PMA
4-methoxyamphetamine
Studies and references cited across this article, graded by evidence strength.
Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.
Data points an editor reviewed and accepted for publication.
Value Provenance
Dosing
oraltrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 10 mg | 10 mg | low |
| Low | 20–40 mg | 20–40 mg | low |
| Common | 40–60 mg | 40–60 mg | low |
| Strong | 60–80 mg | 60–80 mg | low |
| Heavy | 80+ mg | 80+ mg | low |
| Editorial | Dose values carried forward from existing Psychedex database (seed brief: threshold 10 mg, light 20–40 mg, common 40–60 mg). No controlled human dosing studies exist. These values are unverified community-derived estimates. The narrow therapeutic index means doses at the upper end (≥40 mg) carry serious toxicity risk — fatal blood concentrations have been documented at levels achievable from two to three ecstasy-strength tablets. All tiers require editorial verification. | ||
ReasoningReasoningDose values carried forward from existing Psychedex database (seed brief: threshold 10 mg, light 20–40 mg, common 40–60 mg). No controlled human dosing studies exist. These values are unverified community-derived estimates. The narrow therapeutic index means doses at the upper end (≥40 mg) carry serious toxicity risk — fatal blood concentrations have been documented at levels achievable from two to three ecstasy-strength tablets. All tiers require editorial verification. Evidence basis: community_consensus_small | |||
Duration
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 60–120 minutes | 60–120 minutes | medium |
| Editorial | Onset of 60–90 minutes to 2+ hours consistently described across multiple sources: Refstad 2003 (case report), Rojek 2016 (case series), ADF and Release resources. This is the most reliably documented pharmacokinetic parameter for PMA. | ||
ReasoningReasoningOnset of 60–90 minutes to 2+ hours consistently described across multiple sources: Refstad 2003 (case report), Rojek 2016 (case series), ADF and Release resources. This is the most reliably documented pharmacokinetic parameter for PMA. Evidence basis: published_case_series | |||
| Come uptrace | 30–60 minutes | 30–60 minutes | low |
| Editorial | Inferred from MDMA-class analogy. No specific PMA come-up duration data in published literature. Adjusted for PMA's generally slower kinetic profile. | ||
ReasoningReasoningInferred from MDMA-class analogy. No specific PMA come-up duration data in published literature. Adjusted for PMA's generally slower kinetic profile. Evidence basis: structural_analogy | |||
| Peaktrace | 1.5–3 hours | 1.5–3 hours | low |
| Editorial | Inferred from case report descriptions of sustained toxicity and MDMA-class analogy. No controlled duration data published for PMA. | ||
ReasoningReasoningInferred from case report descriptions of sustained toxicity and MDMA-class analogy. No controlled duration data published for PMA. Evidence basis: structural_analogy | |||
| Offsettrace | 1.5–2 hours | 1.5–2 hours | low |
| Editorial | Inferred from MDMA-class analogy. No specific offset data in published literature. | ||
ReasoningReasoningInferred from MDMA-class analogy. No specific offset data in published literature. Evidence basis: structural_analogy | |||
| Totaltrace | 6–8 hours | 6–8 hours | low |
| Editorial | Estimated 6–8+ hours based on clinical presentations in case reports (ADF, Release resources). No formal duration data from controlled studies. This represents subjective experience duration, not pharmacological half-life. | ||
ReasoningReasoningEstimated 6–8+ hours based on clinical presentations in case reports (ADF, Release resources). No formal duration data from controlled studies. This represents subjective experience duration, not pharmacological half-life. Evidence basis: community_consensus_small | |||
| After effectstrace | 4–12 hours | 4–12 hours | low |
| Editorial | Inferred from community reports describing comedown symptoms (anxiety, depression, fatigue, sleep disruption) lasting several hours to half a day after subjective effects resolve. No published data specific to PMA aftereffect duration. | ||
ReasoningReasoningInferred from community reports describing comedown symptoms (anxiety, depression, fatigue, sleep disruption) lasting several hours to half a day after subjective effects resolve. No published data specific to PMA aftereffect duration. Evidence basis: community_consensus_small | |||
Safety
Toxicity Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Acute | critical | critical | high |
| Chronic | moderate | moderate | high |
| Organs Affected | cardiovascular, central_nervous_system, kidney, liver, musculoskeletal | cardiovascular, central_nervous_system, kidney, liver, musculoskeletal | high |
| Editorial | Acute toxicity classified as critical based on documented fatalities at doses close to active range across multiple independent forensic case series (Rojek 2016, Johansen 2003, Becker 2003, Jang 2016). Chronic toxicity classified as moderate: SERT down-regulation documented in animal studies (Callaghan 2006) but no human long-term data exist; downgraded from high because evidence is animal-only. | ||
ReasoningReasoningAcute toxicity classified as critical based on documented fatalities at doses close to active range across multiple independent forensic case series (Rojek 2016, Johansen 2003, Becker 2003, Jang 2016). Chronic toxicity classified as moderate: SERT down-regulation documented in animal studies (Callaghan 2006) but no human long-term data exist; downgraded from high because evidence is animal-only. Evidence basis: published_case_series | |||
Dependence Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Physical | none | none | medium |
| Psychological | low | low | medium |
| Compulsive Redosing | moderate | moderate | medium |
| Dose Escalation | low | low | medium |
| Editorial | Dependence profile based on animal self-administration data (Corrigall 1992: PMA not self-administered; Woolverton 1997: fails amphetamine substitution in primates) and ADF community resource noting no documented physical withdrawal. Compulsive re-dosing risk rated moderate due to the delayed onset/re-dosing dynamic, not reinforcement-driven compulsion. | ||
ReasoningReasoningDependence profile based on animal self-administration data (Corrigall 1992: PMA not self-administered; Woolverton 1997: fails amphetamine substitution in primates) and ADF community resource noting no documented physical withdrawal. Compulsive re-dosing risk rated moderate due to the delayed onset/re-dosing dynamic, not reinforcement-driven compulsion. Evidence basis: animal_study | |||
Withdrawal Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Severity | none | none | low |
| Symptoms | — | — | low |
| Fatal | No | No | low |
| Medical Supervision | Not required | Not required | low |
| Editorial | Physical withdrawal from PMA has not been documented (ADF 2023). Animal self-administration data show no reinforcing properties. No human withdrawal data exist. | ||
ReasoningReasoningPhysical withdrawal from PMA has not been documented (ADF 2023). Animal self-administration data show no reinforcing properties. No human withdrawal data exist. Evidence basis: animal_study | |||
Tolerance Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Buildup | moderate | moderate | low |
| Half-life | — | — | low |
| Full Reset | — | — | low |
| Cross-tolerances | MDMA, PMMA, MDA, 4-MTA | MDMA, PMMA, MDA, 4-MTA | low |
| Editorial | Tolerance mechanism based on Callaghan et al. (2006) showing 53% SERT binding reduction after repeated dosing in rats. Buildup rated moderate by analogy with MDMA-class tolerance. No human data on tolerance kinetics. Cross-tolerances inferred from shared serotonergic releasing agent mechanism. | ||
ReasoningReasoningTolerance mechanism based on Callaghan et al. (2006) showing 53% SERT binding reduction after repeated dosing in rats. Buildup rated moderate by analogy with MDMA-class tolerance. No human data on tolerance kinetics. Cross-tolerances inferred from shared serotonergic releasing agent mechanism. Evidence basis: animal_study | |||
Effects & Profile
Contraindications
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| respiratory asthmatrace | relative | relative | medium |
| Editorial | ADF lists asthma as contraindication. Respiratory failure documented in Vevelstad et al. 2012 (PMMA/PMA epidemic data). | ||
ReasoningReasoningADF lists asthma as contraindication. Respiratory failure documented in Vevelstad et al. 2012 (PMMA/PMA epidemic data). | |||
| other MAO inhibitor therapytrace | absolute | absolute | high |
| Editorial | Directly supported by Freezer et al. 2005 and Stanley et al. 2007 (moclobemide interaction data). PMA's own MAO-A Ki of 0.22 µM (Green 1980) makes any additional MAO inhibition mechanistically catastrophic. | ||
ReasoningReasoningDirectly supported by Freezer et al. 2005 and Stanley et al. 2007 (moclobemide interaction data). PMA's own MAO-A Ki of 0.22 µM (Green 1980) makes any additional MAO inhibition mechanistically catastrophic. | |||
| cardiovascular hypertensiontrace | absolute | absolute | high |
| Editorial | Cardiovascular conditions listed as contraindication by ADF resource. Cardiovascular collapse documented as primary cause of death in multiple forensic case series (Rojek 2016, Caldicott 2003, Johansen 2003). | ||
ReasoningReasoningCardiovascular conditions listed as contraindication by ADF resource. Cardiovascular collapse documented as primary cause of death in multiple forensic case series (Rojek 2016, Caldicott 2003, Johansen 2003). | |||
| cardiovascular cardiac arrhythmiastrace | absolute | absolute | medium |
| Editorial | Inferred from documented cardiovascular collapse as cause of death (Rojek 2016, Johansen 2003) and ADF contraindication listing. Class-level amphetamine cardiovascular risk. | ||
ReasoningReasoningInferred from documented cardiovascular collapse as cause of death (Rojek 2016, Johansen 2003) and ADF contraindication listing. Class-level amphetamine cardiovascular risk. | |||
| neurological epilepsytrace | absolute | absolute | high |
| Editorial | Seizures documented in Refstad 2003 and Vevelstad et al. 2012. ADF lists epilepsy as contraindication. | ||
ReasoningReasoningSeizures documented in Refstad 2003 and Vevelstad et al. 2012. ADF lists epilepsy as contraindication. | |||
| hepatic hepatic impairmenttrace | relative | relative | medium |
| Editorial | CYP2D6 involvement inferred from PMMA metabolism data (Vevelstad et al. 2017). Liver failure documented in case reports (Johansen 2003, Nicol 2015). | ||
ReasoningReasoningCYP2D6 involvement inferred from PMMA metabolism data (Vevelstad et al. 2017). Liver failure documented in case reports (Johansen 2003, Nicol 2015). | |||
| renal renal impairmenttrace | relative | relative | medium |
| Editorial | Acute kidney failure documented in case reports (Johansen 2003, Nicol 2015). Rhabdomyolysis incidence of 30.5% in amphetamine class (Amanollahi 2023). | ||
ReasoningReasoningAcute kidney failure documented in case reports (Johansen 2003, Nicol 2015). Rhabdomyolysis incidence of 30.5% in amphetamine class (Amanollahi 2023). | |||
| pregnancy breastfeeding pregnancytrace | absolute | absolute | medium |
| Editorial | Class-level amphetamine contraindication. No PMA-specific reproductive data. The critical acute toxicity profile makes any exposure during pregnancy unacceptable. | ||
ReasoningReasoningClass-level amphetamine contraindication. No PMA-specific reproductive data. The critical acute toxicity profile makes any exposure during pregnancy unacceptable. | |||
Timeline Phases
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 3600–7200 sec(i=0.05) | 3600–7200 sec(i=0.05) | low |
| Editorial | No controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | ||
ReasoningReasoningNo controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | |||
| Come uptrace | 1800–3600 sec(i=0.30) | 1800–3600 sec(i=0.30) | low |
| Editorial | No controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | ||
ReasoningReasoningNo controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | |||
| Peaktrace | 5400–10800 sec(i=1.00) | 5400–10800 sec(i=1.00) | low |
| Editorial | No controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | ||
ReasoningReasoningNo controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | |||
| Plateautrace | 5400–7200 sec(i=0.50) | 5400–7200 sec(i=0.50) | low |
| Editorial | No controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | ||
ReasoningReasoningNo controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | |||
| Resolutiontrace | 3600–7200 sec(i=0.20) | 3600–7200 sec(i=0.20) | low |
| Editorial | No controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | ||
ReasoningReasoningNo controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | |||
| Afterglowtrace | 14400–43200 sec(i=0.05) | 14400–43200 sec(i=0.05) | low |
| Editorial | No controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | ||
ReasoningReasoningNo controlled human pharmacokinetic or duration studies exist for PMA. All timing data inferred from clinical case report presentations and community reports. Onset of 60\u2013120+ minutes is consistently described across multiple sources (Refstad 2003, Rojek 2016, Release, ADF). Total duration estimated 6\u20138+ hours from case reports. Phase breakdowns are extrapolated from MDMA-class analogy with adjustment for PMA's delayed onset and prolonged activity. | |||
Dose Tier Summaries
At threshold doses, effects are subtle and may be difficult to distinguish from placebo. Slight mood elevation, mild increase in sociability, and faint sensory brightening may be noted. Physical awareness may include a barely perceptible increase in heart rate and very mild stimulation. The extremely slow onset (60–120+ minutes) means threshold effects may not be recognized until well after ingestion. Given PMA's narrow therapeutic index, even threshold doses carry disproportionate risk relative to better-characterized entactogens.
No controlled human dosing studies exist. Threshold value of ~10 mg oral is from community-derived data (seed brief), not clinical measurement. The narrow margin between active and lethal doses makes all dose tier descriptions safety-critical.
ReasoningReasoning
No controlled human dosing studies exist. Threshold value of ~10 mg oral is from community-derived data (seed brief), not clinical measurement. The narrow margin between active and lethal doses makes all dose tier descriptions safety-critical.
Evidence basis: community_consensus_small
Mild stimulation becomes noticeable, with increased energy, slight emotional warmth, and enhanced sensory appreciation. Some users report faint visual brightening and increased sociability. The entactogenic character begins to emerge at this range. Physically, mild tachycardia, slight elevation in body temperature, pupil dilation, and decreased appetite are expected. Jaw tension (bruxism) may appear. The onset remains delayed (60–120+ minutes), and the temptation to re-dose during this window is the primary safety concern at any dose level.
Light range (~20–40 mg oral) from community-derived seed data. No controlled studies confirm these thresholds. Effects extrapolated from case report descriptions and MDMA-class analogy. All values require editorial verification.
ReasoningReasoning
Light range (~20–40 mg oral) from community-derived seed data. No controlled studies confirm these thresholds. Effects extrapolated from case report descriptions and MDMA-class analogy. All values require editorial verification.
Evidence basis: community_consensus_small
The full subjective profile manifests: moderate stimulation, emotional warmth and feelings of closeness, heightened sensory perception, and possible visual disturbances consistent with PMA's partial hallucinogenic classification. Cognitive euphoria and prosocial effects reach their clearest expression. Physical effects intensify: tachycardia, elevated blood pressure, sweating, bruxism, and pupil dilation become pronounced. Body temperature begins to rise noticeably. Nausea and dizziness may occur. Duration extends to an estimated 6–8+ hours. At this range, PMA's narrow therapeutic window becomes critically relevant. Any additional dosing risks crossing into dangerous territory. Hot environments and physical exertion amplify hyperthermia risk.
Common range (~40–60 mg oral) from community-derived seed data. No controlled human studies exist. The narrow margin between common and toxic doses is well-documented in forensic literature. Effects described from case reports and ADF resource.
ReasoningReasoning
Common range (~40–60 mg oral) from community-derived seed data. No controlled human studies exist. The narrow margin between common and toxic doses is well-documented in forensic literature. Effects described from case reports and ADF resource.
Evidence basis: community_consensus_small
Effects become intense and increasingly dominated by adverse symptoms. Strong stimulation, pronounced emotional intensity, and visual disturbances are reported alongside significant anxiety and agitation. The entactogenic warmth may give way to dysphoria and restlessness. Physical effects approach dangerous thresholds: marked tachycardia, significant hyperthermia, profuse sweating, muscle spasms, and irregular eye movements. The risk of serotonin syndrome features (clonus, rigidity, hyperthermia) increases sharply. This dose range overlaps with documented toxic presentations. Sleep is impossible for many hours. The functional impairment is severe and medical monitoring is advisable.
No controlled data define a 'strong' tier. Inferred from the narrow gap between common doses and fatal blood concentrations. Case reports describe severe toxicity at doses modestly above the common range. Strong doses are essentially entering the toxic range for PMA.
ReasoningReasoning
No controlled data define a 'strong' tier. Inferred from the narrow gap between common doses and fatal blood concentrations. Case reports describe severe toxicity at doses modestly above the common range. Strong doses are essentially entering the toxic range for PMA.
Evidence basis: published_case_series
At heavy doses, PMA produces a clinical picture dominated by life-threatening toxicity rather than recreational effects. Severe hyperthermia (>40°C), cardiovascular crisis, seizures, and multi-organ failure become probable rather than possible outcomes. The distinction between a 'heavy recreational dose' and an overdose is functionally nonexistent for PMA. Fatal blood concentrations have been documented at levels consistent with ingestion of two to three typical ecstasy-strength tablets. Rhabdomyolysis, disseminated intravascular coagulation, and acute kidney failure are documented complications. This dose range constitutes a medical emergency. Immediate emergency services are required.
Heavy doses of PMA are essentially overdose territory. Fatal cases document blood concentrations achievable from modest oral doses. No safe 'heavy' recreational dose can be meaningfully defined for PMA given its narrow therapeutic index.
ReasoningReasoning
Heavy doses of PMA are essentially overdose territory. Fatal cases document blood concentrations achievable from modest oral doses. No safe 'heavy' recreational dose can be meaningfully defined for PMA given its narrow therapeutic index.
Evidence basis: published_case_series
History
backfill Jun 4, 2026
Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.
Sources
- [1]moderatep-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo.Green AL, El Hait MA · 1980 · The Journal of Pharmacy and Pharmacologypubmed 61030559 claims checked9 verified
- [2]moderateEffects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide.Freezer A, Salem A, Irvine RJ · 2005 · Brain Researchpubmed 158044997 claims checked7 verified
- [3]moderateDifferences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry.Callaghan PD, Irvine RJ, Daws LC · 2005 · Neurochemistry Internationalpubmed 159792096 claims checked5 verified1 partial
- [4]weak
- [5]moderateComparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.Hegadoren KM, Martin-Iverson MT, Baker GB · 1995 · Psychopharmacologypubmed 76178224 claims checked3 verified1 partial
- [6]moderatePharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia.Jaehne EJ, Salem A, Irvine RJ · 2007 · Psychopharmacologypubmed 175304744 claims checked4 verified
- [7]moderateThe reinforcing and discriminative stimulus properties of para-ethoxy- and para-methoxyamphetamine.Corrigall WA, Robertson JM, Coen KM, Lodge BA · 1992 · Pharmacology, Biochemistry, and Behaviorpubmed 15390675 claims checked5 verified
- [8]weakMedicolegal aspects of PMA-related deaths.Rojek S, Bochełała F, Kula K, Maciów-Głąb M, Kłys M · 2016 · Legal Medicine (Tokyo)doi.org/10.1016/j.legalmed.2016.06.002pubmed 274973368 claims checked4 verified2 partial2 inconclusive
- [9]weakParamethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects.Refstad S · 2003 · Acta Anaesthesiologica Scandinavicapubmed 146163318 claims checked3 verified5 inconclusive
- [10]weakAmphetamine derivative fatalities in South Australia--is 'Ecstasy' the culprit?Byard RW, Gilbert J, James R, Lokan RJ · 1998 · The American Journal of Forensic Medicine and Pathologypubmed 97600942 claims checked2 inconclusive
- [11]weak
- [12]moderateRepeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine.Callaghan PD, Farrand K, Salem A, Hughes P, Daws LC, Irvine RJ · 2006 · European Journal of Pharmacologypubmed 169259935 claims checked5 verified
- [13]weakDEA Scheduling: PMA as Schedule I hallucinogen (38 FR 26447, July 2, 1973)US Drug Enforcement Administration · 1973linkno claims checked
- [14]weakUK Misuse of Drugs Act 1971, Modification Order 1977 (S.I. 1977/1243)UK Government · 1977linkno claims checked
- [15]weakDancing with 'death': p-methoxyamphetamine overdose and its acute management.Caldicott DG, Edwards NA, Kruys A, Kirkbride KP, Sims DN, Byard RW, Prior M, Irvine RJ · 2003 · Journal of Toxicology. Clinical Toxicologypubmed 127338523 claims checked2 verified1 inconclusive
- [16]weakThe PMMA epidemic in Norway: comparison of fatal and non-fatal intoxicationsVevelstad M, Øiestad EL, Middelkoop G, Hasvold I, Lilleng P, Delaveris GJ, Eggen T, Mørland J, Arnestad M · 2012 · Forensic Science International
- [17]moderateAnise oil as para-methoxyamphetamine (PMA) precursor.Waumans D, Bruneel N, Tytgat J · 2003 · Forensic Science Internationalpubmed 127427052 claims checked2 verified
- [18]weakThree fatal cases of PMA and PMMA poisoning in Denmark.Johansen SS, Hansen AC, Müller IB, Lundemose JB, Franzmann MB · 2003 · Journal of Analytical Toxicologypubmed 128207496 claims checked2 verified1 partial3 inconclusive
- [19]weak
- [20]weakDeaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case seriesNicol JJ, Yarema MC, Jones GR, Martz W, Purssell RA, MacDonald JC, Wishart I, Durigon M, Tzemis D, Buxton JA · 2015 · CMAJ Open
- [21]moderateStudies on Para-Methoxymethamphetamine (PMMA) Metabolite Pattern and Influence of CYP2D6 Genetics in Human Liver Microsomes and Authentic Samples from Fatal PMMA IntoxicationsVevelstad M, Øiestad EL, Nerem E, Arnestad M, Bogen IL · 2017 · Drug Metabolism and Disposition
- [22]moderate
- [23]moderatePotentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.Hewton R, Salem A, Irvine RJ · 2007 · Clinical and Experimental Pharmacology & Physiologypubmed 177140936 claims checked6 verified
- [24]moderateEffect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain NeurotransmittersGołembiowska K, Jurczak A, Kamińska K, Noworyta K, Górska A · 2015 · Neurotoxicity Research
- [25]moderateNovel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalingLiechti ME · 2015 · Swiss Medical Weekly
- [26]moderateThe stimulus properties of para-methoxyamphetamine: a nonessential serotonergic component.Winter JC · 1984 · Pharmacology, Biochemistry, and Behaviorpubmed 65469922 claims checked2 verified
- [27]moderateMonoamine transporter and receptor interaction profiles of a new series of designer cathinonesSimmler LD, Rickli A, Hoener MC, Liechti ME · 2014 · Neuropharmacology
- [28]moderateThe effects of co-administration of 3,4-methylenedioxymethamphetamine ('ecstasy') or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats.Stanley N, Salem A, Irvine RJ · 2007 · Neurosciencepubmed 173064653 claims checked2 verified1 inconclusive
- [29]moderateThe effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain.Straiko MM, Coolen LM, Zemlan FP, Gudelsky GA · 2007 · Neurosciencepubmed 170840361 claim checked1 verified
- [30]moderateP-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G · 2003 · Addiction Biologypubmed 146908771 claim checked1 verified
- [31]moderateThe Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish.Ponzoni L, Braida D, Bondiolotti G, Sala M · 2017 · Frontiers in Psychiatry
- [32]weakA fatal case of paramethoxyamphetamine poisoning and its detection in hair.Jang M, Yang W, Jeong S, Park S, Kim J · 2016 · Forensic Science International
- [33]moderateOverview of amphetamine-type stimulant mortality data--UK, 1997-2007.Schifano F, Corkery J, Naidoo V, Oyefeso A, Ghodse H · 2010 · Neuropsychobiology
- [34]strongIncidence of rhabdomyolysis occurrence in psychoactive substances intoxication: a systematic review and meta-analysis.Amanollahi A, Babeveynezhad T, Sedighi M, Shadnia S, Akbari S · 2023 · Scientific Reports
- [35]moderateEffects of para-methoxyamphetamine (PMA) on agonistic encounters between male mice.Martín-López M, Muela AT, Cavas M, Navarro JF · 2018 · Pharmacology, Biochemistry, and Behavior
- [36]moderateEffects of some phenylethylamines in rhesus monkeys trained to discriminate (+)-amphetamine from saline.Woolverton WL, English JA · 1997 · Drug and Alcohol Dependencepubmed 90887791 claim checked1 verified
- [37]weakA fatal paramethoxymethamphetamine intoxicationBecker J, Neis P, Röhrich J, Zörntlein S · 2003 · Legal Medicine (Tokyo)pubmed 129355731 claim checked1 verified
Claim Verification
Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.
summary11 claims6verified2partial3inconclusive
partialPara-methoxyamphetamine (PMA, 4-MA) is a substituted amphetamine with stimulant and entactogenic properties, though animal behavioral data also support hallucinogenic classification[5]model confidence 88%
The abstract actively contradicts the 'stimulant and entactogenic properties' framing — it explicitly classifies PMA as a hallucinogen distinct from entactogens and stimulants. The hallucinogenic part is supported, but the primary framing of the claim is undermined.
PMA classified as hallucinogen (not entactogen or stimulant) by behavioral cluster analysis. PMA's behavioral profile distinct from MDMA class.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusivePMA occupies a uniquely dangerous position within its class: oral onset is delayed to 60–120+ minutes versus 30–60 minutes for MDMA, effects persist an estimated 6–8+ hours, and the margin between active and lethal doses is narrow.[9]model confidence 75%
The abstract confirms slower onset leading to re-dosing danger, which is directionally correct, but provides no specific timing figures (60–120+ min, 6–8+ hrs) to verify the quantitative claims.
Discusses slower onset leading to re-dosing danger.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusivePMA occupies a uniquely dangerous position within its class: oral onset is delayed to 60–120+ minutes versus 30–60 minutes for MDMA, effects persist an estimated 6–8+ hours, and the margin between active and lethal doses is narrow.[8]model confidence 75%
The abstract confirms slower onset and re-dosing danger but does not provide specific onset timing figures (60–120+ min) or duration (6–8+ hrs) to verify the quantitative assertions.
PMA more potent but slower onset than MDMA leads to redosing danger.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveRecurring death clusters followed: Ontario 1973, South Australia in the 1990s, approximately 20 global deaths in 2000–2001, and 20–29 annual deaths in England and Wales during 2012–2013 — almost invariably when PMA was sold as MDMA in ecstasy tablets[10]model confidence 70%
Abstract not available; cannot verify any specific claims.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA acts through three converging serotonergic mechanisms: potent reversible MAO-A inhibition (Ki = 0.22 µM, >20-fold more potent than amphetamine), SERT-mediated 5-HT release producing ~360% striatal elevation in rats, and more efficacious 5-HT reuptake inhibition than MDMA in hippocampal regions served exclusively by SERT[1]model confidence 95%
This citation directly supports the MAO-A inhibition component of the three-mechanism claim. Ki = 0.22 µM and >20-fold potency over amphetamine are confirmed exactly.
PMA is 20x more potent than (+)-amphetamine as MAO-A inhibitor. Ki = 0.22 μM for MAO-A (mouse brain).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA acts through three converging serotonergic mechanisms: potent reversible MAO-A inhibition (Ki = 0.22 µM, >20-fold more potent than amphetamine), SERT-mediated 5-HT release producing ~360% striatal elevation in rats, and more efficacious 5-HT reuptake inhibition than MDMA in hippocampal regions served exclusively by SERT[2]model confidence 95%
This citation directly supports the ~360% striatal 5-HT elevation and the MAO-A inhibition components of the three-mechanism claim.
PMA produced 360% increase in extracellular 5-HT (MDMA 590%). PMA is MAO-A inhibitor.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA acts through three converging serotonergic mechanisms: potent reversible MAO-A inhibition (Ki = 0.22 µM, >20-fold more potent than amphetamine), SERT-mediated 5-HT release producing ~360% striatal elevation in rats, and more efficacious 5-HT reuptake inhibition than MDMA in hippocampal regions served exclusively by SERT[3]model confidence 95%
This citation directly supports the SERT-mediated release and more efficacious hippocampal SERT inhibition components of the three-mechanism claim.
PMA causes less neurotransmitter release than MDMA in striatum but is a more efficacious SERT inhibitor in hippocampus. Evoked 5-HT release via SERT mechanism.
checked by claude-sonnet-4-6 · Apr 25, 2026
partialPMA's acute toxicity is critical: fatal blood concentrations range from 0.57 to 27 mg/L, with hyperthermia exceeding 40–42°C as the primary lethal mechanism — more severe than MDMA, cocaine, or methamphetamine[8]model confidence 82%
This paper reports fatal concentrations of 10–27 mg/L, confirming the upper bound. The lower bound of 0.57 mg/L is not from this paper. The abstract also identifies 'acute cardiorespiratory failure' as cause of death rather than hyperthermia specifically, and does not make the MDMA/cocaine/meth comparison.
Three fatal PMA cases with blood concentrations 10-27 mg/L. Cause of death: acute cardiorespiratory failure.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA's acute toxicity is critical: fatal blood concentrations range from 0.57 to 27 mg/L, with hyperthermia exceeding 40–42°C as the primary lethal mechanism — more severe than MDMA, cocaine, or methamphetamine[6]model confidence 93%
Abstract directly confirms PMA produces more severe hyperthermia than MDMA, cocaine, and methamphetamine, supporting the hyperthermia severity comparison.
PMA associated with more severe hyperthermia than MDMA, cocaine, methamphetamine in humans.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA does not maintain self-administration in rats, suggesting low dependence liability[7]model confidence 98%
Abstract directly confirms PMA does not maintain self-administration in rats and supports low addiction potential.
PMA does not maintain self-administration in rats (not reinforcing)... Supports low addiction potential.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedRepeated administration reduces cortical SERT binding by 53% without depleting 5-HT — a tolerance mechanism distinct from MDMA's neurotoxic pattern[12]model confidence 98%
Abstract directly confirms 53% reduction in cortical SERT binding without reduction in 5-HT content, described as different from MDMA's neurotoxic profile.
Repeated PMA (10-20 mg/kg for 4 days) reduced cortical SERT binding (53%) but unlike MDMA did not reduce cortical 5-HT content. Different long-term neurotoxic profile from MDMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
history7 claims5verified2inconclusive
inconclusiveByard et al. documented a series of amphetamine-derivative fatalities in South Australia during this period, analyzing why deaths had increased markedly[10]model confidence 70%
Abstract not available; cannot verify the specific claim. The scope description is consistent, but no text is provided for assessment.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedCaldicott et al. later documented South Australian PMA overdose cases and provided management guidelines, noting the compound was known locally under the street name "death".[15]model confidence 93%
Abstract confirms a South Australian PMA overdose case with management guidelines. The street name 'death' is embedded in the paper's own title ('Dancing with death'), making this fully supported.
Case of PMA overdose in South Australia; review of literature and management suggestions.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedJohansen et al. described three Danish fatal cases from this period.[18]model confidence 99%
Abstract directly confirms three fatal cases in Denmark in 2000.
Three fatal cases in Denmark 2000.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedFrom July 2010 to January 2011, Norway experienced 12 fatal para-methoxymethamphetamine (PMMA) intoxications and 22 non-fatal cases within a population of 4.8 million — a concentrated epidemic that triggered broad media attention and an EMCDDA advisory[16]model confidence 95%
Abstract directly confirms 12 fatal and 22 non-fatal PMMA cases in Norway July 2010–January 2011. Population figure and media/EMCDDA detail are not in abstract but are minor contextual additions not contradicted.
12 fatal and 22 non-fatal PMMA cases in Norway July 2010-January 2011.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA was detected as a metabolite in these cases at low concentrations (0.00–0.26 mg/L).[16]model confidence 99%
Abstract exactly confirms PMA found as PMMA metabolite at 0.00–0.26 mg/L.
PMA found as PMMA metabolite (0.00-0.26 mg/L).
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveCanada added PMA to Schedule I of the Controlled Drugs and Substances Act in 2012, following documented deaths in Alberta and British Columbia.[20]model confidence 65%
Abstract documents fatal PMMA/PMA cases in Alberta and British Columbia but makes no mention of Canadian scheduling, the year 2012, or the Controlled Drugs and Substances Act.
PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, then cardiovascular collapse.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA can be synthesized via the Leuckart reaction from 4-methoxyphenylacetone, itself derived from anethole — a constituent of anise oil that is cheap and largely unwatched by precursor control regimes compared to MDMA precursors[17]model confidence 99%
Abstract exactly confirms PMA synthesis from anethole via Leuckart synthesis and that anethole is cheap and unwatched compared to MDMA precursors.
PMA synthesized from anethole (anise oil) via Leuckart synthesis. Precursor anethole is cheap and unwatched unlike MDMA precursors.
checked by claude-sonnet-4-6 · Apr 25, 2026
chemistry2 claims2verified
verifiedThis para-methoxy substitution distinguishes PMA from its N-methylated congener para-methoxymethamphetamine (PMMA), of which PMA is also a metabolite via N-demethylation[21]model confidence 95%
Abstract confirms PMA is a metabolite of PMMA, supporting the metabolic relationship described. N-demethylation is the only chemically possible route.
PMA is a minor metabolite of PMMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA is synthesized via the Leuckart reaction from 4-methoxyphenylacetone, a precursor derived from anethole (a natural constituent of anise oil)[17]model confidence 99%
Abstract exactly confirms Leuckart synthesis from anethole (anise oil).
PMA synthesized from anethole (anise oil) via Leuckart synthesis.
checked by claude-sonnet-4-6 · Apr 25, 2026
pharmacology17 claims15verified2inconclusive
verifiedHewton et al. found in rat substantia nigra microdialysis that PMA produced a 726 ± 287% increase in extracellular 5-HT versus 482 ± 83% for MDMA[23]model confidence 97%
Abstract directly confirms 726% for PMA and 482% for MDMA in the substantia nigra. The ±SD values are not in the abstract but would be in the full paper.
PMA and MDMA both increase extracellular 5-HT (726% and 482% respectively in substantia nigra).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedGreen and El Hait characterized PMA as having a Ki of 0.22 µM for MAO-A in mouse brain in vitro — over 20 times more potent than (+)-amphetamine as an inhibitor of 5-HT oxidation[1]model confidence 99%
Abstract exactly confirms Ki = 0.22 µM for MAO-A in mouse brain and >20x potency over (+)-amphetamine.
PMA is 20x more potent than (+)-amphetamine as MAO-A inhibitor. Ki = 0.22 μM for MAO-A (mouse brain).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedSelectivity for MAO-A over MAO-B is pronounced: Ki for MAO-B is approximately 500 µM (benzylamine substrate, rat liver mitochondria), yielding a selectivity ratio of approximately 2,300-fold. In vivo, PMA was 10 times more active than amphetamine at protecting mouse brain MAO from phenelzine inhibition[1]model confidence 95%
Abstract confirms Ki ~500 µM for MAO-B and 10x greater in vivo potency over amphetamine in protecting against phenelzine. The selectivity ratio of ~2,300 is arithmetically consistent with 500/0.22. Substrate/tissue specifics may be in the full text.
Ki ~500 μM for MAO-B. 10x more active than amphetamine in vivo protecting against phenelzine.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedSelectivity for MAO-A over MAO-B is pronounced: Ki for MAO-B is approximately 500 µM (benzylamine substrate, rat liver mitochondria), yielding a selectivity ratio of approximately 2,300-fold. In vivo, PMA was 10 times more active than amphetamine at protecting mouse brain MAO from phenelzine inhibition[1]model confidence 95%
Duplicate of Pair 18 — same citation, same claim. Abstract confirms Ki ~500 µM for MAO-B and 10x in vivo potency.
Ki ~500 μM for MAO-B. 10x more active than amphetamine in vivo protecting against phenelzine.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedFreezer et al. demonstrated via rat striatal microdialysis that PMA produces approximately 360% increase in extracellular 5-HT, compared with approximately 590% for MDMA under identical conditions[2]model confidence 99%
Abstract exactly confirms 360% increase for PMA and 590% for MDMA.
PMA produced 360% increase in extracellular 5-HT (MDMA 590%).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA-evoked 5-HT release was partially blocked by a SERT inhibitor, confirming SERT-mediated efflux as the release mechanism.[3]model confidence 90%
Abstract confirms evoked 5-HT release via SERT mechanism. The 'partially blocked by SERT inhibitor' is a reasonable characterization of the SERT-mediated finding; the abstract supports SERT as the confirmed release mechanism.
Evoked 5-HT release via SERT mechanism.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedCallaghan et al., using chronoamperometry in anesthetized rats, demonstrated that while PMA causes less total neurotransmitter release than MDMA in the striatum, PMA is a more efficacious inhibitor of 5-HT clearance in the hippocampal CA3 region — a structure where only SERT (not DAT) clears serotonin[3]model confidence 97%
Abstract directly confirms less striatal release than MDMA but greater hippocampal SERT inhibition. The 'CA3 region where only SERT clears serotonin' is a valid characterization consistent with the abstract's scope.
PMA causes less neurotransmitter release than MDMA in striatum but is a more efficacious SERT inhibitor in hippocampus.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedAdding the MAO-A inhibitor clorgyline further potentiated MDMA-induced release (to 1033%) but did not potentiate PMA, because PMA already near-saturates endogenous MAO-A at the doses tested — its own MAO-A inhibitory action is already operative.[23]model confidence 95%
Abstract confirms clorgyline potentiated MDMA but not PMA because PMA already saturates MAO-A. The '1033%' figure is not in the abstract but the directional finding and mechanism are confirmed.
Adding clorgyline potentiated MDMA but not PMA (already saturating MAO-A).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedGołembiowska et al. demonstrated using rat brain microdialysis that PMA (5 and 10 mg/kg) enhances dopamine and 5-HT release in the striatum, nucleus accumbens, and frontal cortex, with increased DA and 5-HT tissue content in nucleus accumbens and frontal cortex[24]model confidence 99%
Abstract exactly confirms all elements: doses, regions (striatum, nucleus accumbens, frontal cortex), DA and 5-HT release, and tissue content changes.
PMA (5, 10 mg/kg) enhanced DA and 5-HT release in rat striatum, nucleus accumbens, and frontal cortex via microdialysis. PMA increased DA tissue content in nucleus accumbens and frontal cortex. PMA increased 5-HT content in nucleus accumbens and frontal cortex.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedSimmler et al. referenced PMA as releasing norepinephrine and 5-HT similarly to PMMA, 4-MTA, and MDMA in comparative in vitro transporter studies, though PMA-specific Ki/EC50 values at DAT and NET were not published[27]model confidence 97%
Abstract directly confirms PMA releases NE and 5-HT similar to PMMA, 4-MTA, and MDMA in comparative in vitro transporter studies.
PMA referenced as releasing NE and 5-HT similar to PMMA, 4-MTA, and MDMA in in vitro transporter studies.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedLiechti classifies para-substituted amphetamines including PMA as serotonergic entactogens (serotonin-preferential releasing agents), similar to MDMA[25]model confidence 97%
Abstract directly confirms para-substituted amphetamines including PMA are classified as serotonin-releasing entactogens in this review.
Para-substituted amphetamines (including PMA) classified as serotonin-releasing entactogens.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedHegadoren et al. classify PMA as a hallucinogen based on behavioral cluster analysis in rats — a classification distinct from both entactogens and stimulants[5]model confidence 99%
Abstract directly and exactly confirms PMA classified as hallucinogen (not entactogen or stimulant) by behavioral cluster analysis, distinct from MDMA class.
PMA classified as hallucinogen (not entactogen or stimulant) by behavioral cluster analysis. PMA's behavioral profile distinct from MDMA class.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedWinter found PMA established clear discriminative stimulus control in rats independent of serotonergic mediation, with partial cross-generalization to LSD[26]model confidence 97%
Abstract directly confirms PMA established clear discriminative stimulus control in rats, with partial LSD cross-generalization. The abstract also states PMA's own stimulus control is not serotonergically mediated.
PMA established clear discriminative stimulus control in rats. LSD-trained subjects showed intermediate response to PMA (partial cross-generalization). PMA's LSD-like effects are serotonergically mediated but PMA's own stimulus control is not.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveOral onset is markedly slower than MDMA — clinical reports describe 60–90 minutes to 2+ hours before subjective effects appear, contributing to the characteristic re-dosing danger[9]model confidence 75%
Abstract confirms slower onset and re-dosing danger, but provides no specific timing figures to verify the quantitative claim of 60–90 minutes to 2+ hours.
Discusses slower onset leading to re-dosing danger.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveOral onset is markedly slower than MDMA — clinical reports describe 60–90 minutes to 2+ hours before subjective effects appear, contributing to the characteristic re-dosing danger[8]model confidence 75%
Abstract confirms slower onset and re-dosing danger but does not provide specific timing figures (60–90 min to 2+ hrs).
PMA more potent but slower onset than MDMA leads to redosing danger.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA is a minor metabolite of PMMA via N-demethylation[21]model confidence 92%
Abstract confirms PMA is a minor metabolite of PMMA. N-demethylation is the only chemically possible route (PMMA has an N-methyl group that PMA lacks), consistent with the abstract's finding.
PMA is a minor metabolite of PMMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedCYP2D6 is involved in PMMA metabolism producing PMA, and by structural analogy CYP2D6 likely plays a role in PMA's own further metabolism[21]model confidence 90%
Abstract confirms CYP2D6 genetics significantly impacts PMMA metabolism and PMA is a PMMA metabolite. The 'structural analogy' inference for PMA's own metabolism is labeled as 'likely' in the claim, appropriately hedged.
CYP2D6 genetics significantly impacts PMMA metabolism. PMA is a minor metabolite of PMMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
receptor pharmacology7 claims7verified
verifiedQualitative data confirm PMA enhances DA release in the striatum, nucleus accumbens, and frontal cortex (5 and 10 mg/kg, rat microdialysis)[24]model confidence 99%
Abstract exactly confirms DA release enhancement in all three regions at 5 and 10 mg/kg via rat microdialysis.
PMA (5, 10 mg/kg) enhanced DA and 5-HT release in rat striatum, nucleus accumbens, and frontal cortex via microdialysis.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedThe Ki for MAO-A is 0.22 µM (mouse brain in vitro, 5-HT substrate), making PMA over 20-fold more potent than (+)-amphetamine at this target[1]model confidence 99%
Abstract exactly confirms Ki = 0.22 µM for MAO-A in mouse brain and >20-fold potency over (+)-amphetamine.
PMA is 20x more potent than (+)-amphetamine as MAO-A inhibitor. Ki = 0.22 μM for MAO-A (mouse brain).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedMAO-B affinity is negligible: Ki ≈ 500 µM (benzylamine substrate, rat liver mitochondria), yielding a selectivity ratio of approximately 2,300-fold for MAO-A over MAO-B.[1]model confidence 95%
Abstract confirms Ki ~500 µM for MAO-B. The ~2,300-fold selectivity ratio is arithmetically correct (500/0.22 ≈ 2,273). Substrate and tissue specifics are consistent with the paper's scope.
Ki ~500 μM for MAO-B.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedCallaghan et al. demonstrated using in vivo chronoamperometry that PMA is a more efficacious inhibitor of 5-HT clearance than MDMA in the hippocampal CA3 region, where SERT is the sole monoamine transporter[3]model confidence 97%
Abstract directly confirms PMA as more efficacious SERT inhibitor in hippocampus than MDMA using chronoamperometry.
PMA causes less neurotransmitter release than MDMA in striatum but is a more efficacious SERT inhibitor in hippocampus.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedFreezer et al. confirmed SERT-mediated release: PMA-evoked striatal 5-HT efflux (~360% of baseline) was partially blocked by a SERT inhibitor.[2]model confidence 92%
Abstract confirms 360% 5-HT increase and identifies SERT as the release mechanism. The 'partially blocked by SERT inhibitor' is consistent with SERT-mediated efflux finding.
PMA produced 360% increase in extracellular 5-HT (MDMA 590%). PMA is MAO-A inhibitor.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedSimmler et al. noted PMA releases NE and 5-HT with a profile similar to PMMA, 4-MTA, and MDMA, but PMA-specific transporter affinity values were not reported.[27]model confidence 99%
Abstract directly confirms PMA referenced as releasing NE and 5-HT similar to PMMA, 4-MTA, and MDMA in comparative transporter studies.
PMA referenced as releasing NE and 5-HT similar to PMMA, 4-MTA, and MDMA in in vitro transporter studies.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedThe receptor-level basis for PMA's hallucinogenic properties — suggested by partial LSD cross-generalization in drug discrimination and 5-HT₂A/C involvement in zebrafish reward models — remains uncharacterized at the binding affinity level.[26]model confidence 90%
Abstract directly confirms partial LSD cross-generalization, which is the drug discrimination evidence cited for hallucinogenic properties. The zebrafish aspect is from another citation.
LSD-trained subjects showed intermediate response to PMA (partial cross-generalization). PMA's LSD-like effects are serotonergically mediated.
checked by claude-sonnet-4-6 · Apr 25, 2026
neuroscience12 claims11verified1inconclusive
verifiedPMA enhances DA release in the striatum, nucleus accumbens, and frontal cortex at 5 and 10 mg/kg in rats[24]model confidence 99%
Abstract exactly confirms this claim in full.
PMA (5, 10 mg/kg) enhanced DA and 5-HT release in rat striatum, nucleus accumbens, and frontal cortex via microdialysis.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedRepeated PMA exposure (10–20 mg/kg for 4 days) produces 53% reduction in cortical SERT binding without corresponding depletion of 5-HT tissue content[12]model confidence 99%
Abstract exactly confirms 53% SERT reduction without 5-HT content depletion under the specified regimen.
Repeated PMA (10-20 mg/kg for 4 days) reduced cortical SERT binding (53%) but unlike MDMA did not reduce cortical 5-HT content.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedIn mouse aggression models, PMA (2–12 mg/kg i.p.) reduces offensive behavior with a complex dose-dependent profile: lower doses increase social investigation, while higher doses produce anxiogenic effects and a unique immobility not seen with MDMA.[35]model confidence 99%
Abstract exactly confirms all elements: dose range, reduction in offensive behavior, social investigation at low doses, anxiogenic effects at higher doses, and immobility unique to PMA.
PMA (2-12 mg/kg i.p.) reduced offensive behaviors in mice. Complex dose-dependent profile: lowest dose showed social investigation and approach; higher doses showed anxiogenic effects similar to MDMA, plus immobility unique to PMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedSerotonin toxicity cascade: PMA exemplifies the convergent model of serotonin syndrome pathogenesis: simultaneous release, reuptake blockade, and catabolism inhibition produce a serotonergic "triple hit" that overwhelms homeostatic regulation[23]model confidence 88%
Abstract demonstrates two of the three serotonergic mechanisms (release and MAO-A inhibition). The 'triple hit' synthesis is a reasonable editorial characterization of the converging mechanisms shown in this and related papers.
PMA and MDMA both increase extracellular 5-HT (726% and 482% respectively in substantia nigra). PMA has greater potency as MAO-A inhibitor.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedDoes CYP2D6 polymorphism (poor metabolizer phenotype) influence PMA toxicity risk, as demonstrated for PMMA?[21]model confidence 92%
Abstract directly confirms that CYP2D6 genetics significantly impacts PMMA metabolism, supporting the claim that this question is well-grounded and demonstrated for PMMA.
CYP2D6 genetics significantly impacts PMMA metabolism.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedIn the striatum, PMA elevates 5-HT to approximately 360% of baseline; in the substantia nigra, to 726 ± 287%[2]model confidence 97%
This citation covers the striatal 360% figure exactly. The substantia nigra data (726%) is from citation [12].
PMA produced 360% increase in extracellular 5-HT (MDMA 590%).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedIn the striatum, PMA elevates 5-HT to approximately 360% of baseline; in the substantia nigra, to 726 ± 287%[23]model confidence 97%
This citation covers the substantia nigra 726% figure exactly.
PMA and MDMA both increase extracellular 5-HT (726% and 482% respectively in substantia nigra).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedThe magnitude of DA release is modest compared to classical stimulants, consistent with PMA's failure to maintain self-administration[7]model confidence 88%
Abstract confirms PMA fails to maintain self-administration in rats. The link between modest DA release and reinforcement failure is a well-established neuroscience inference consistent with the paper's findings.
PMA does not maintain self-administration in rats (not reinforcing). Supports low addiction potential.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveAmbient temperature dramatically amplifies this effect — at 30°C versus 22°C, the combination of PMA and moclobemide produced 4.7-fold higher 5-HT outflow.[28]model confidence 65%
Abstract confirms 1450% at 30°C with moclobemide + PMA. However, the 4.7-fold comparison requires knowing the room-temperature baseline for the same combination, which is not provided in the abstract. Cannot verify the specific fold-difference from the abstract alone.
At elevated temperature (30°C), moclobemide + PMA produced 1450% peak 5-HT increase.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedNeither PMA nor the selective 5-HT neurotoxin 5,7-DHT produced increased cleaved MAP-tau, a marker of cytoskeletal disruption associated with dopaminergic neurotoxicants.[29]model confidence 90%
Abstract confirms PMA does not affect C-tau (cleaved MAP-tau), consistent with the claim. The 5,7-DHT finding is not in the abstract but PMA's lack of C-tau effect is directly confirmed.
PMA and MDMA produce selective 5-HT depletion without affecting C-tau (CNS toxicity marker) unlike AMPH/METH.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedHegadoren et al. classified PMA as a hallucinogen based on behavioral cluster analysis — distinct from both psychomotor stimulants and entactogens[5]model confidence 99%
Abstract exactly confirms PMA classified as hallucinogen (not entactogen or stimulant) by behavioral cluster analysis.
PMA classified as hallucinogen (not entactogen or stimulant) by behavioral cluster analysis. PMA's behavioral profile distinct from MDMA class.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedIncentive salience model: PMA's failure to maintain self-administration in rats despite producing conditioned place preference in zebrafish suggests a dissociation between wanting (mesolimbic DA-driven incentive salience) and liking (hedonic value)[7]model confidence 85%
Abstract confirms the self-administration failure component. The zebrafish CPP data would come from another citation. The incentive salience theoretical framing is editorial synthesis, but the self-administration finding cited here is directly confirmed.
PMA does not maintain self-administration in rats (not reinforcing).
checked by claude-sonnet-4-6 · Apr 25, 2026
pharmacokinetic detail5 claims3verified2inconclusive
verifiedJang et al. detected PMA in hair samples from a fatal case, demonstrating incorporation into keratinized tissue suitable for retrospective exposure confirmation.[32]model confidence 99%
Abstract directly confirms PMA detected in hair (20.1 ng/mg) and notes this is the first report of PMA in hair.
Hair analysis showed PMA at 20.1 ng/mg. First report of PMA in hair.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedThe delayed onset is the primary driver of re-dosing behavior and accidental overdose.[8]model confidence 95%
Abstract directly supports this: slower onset than MDMA leads to re-dosing danger, consistent with the claim that delayed onset drives accidental overdose.
PMA more potent but slower onset than MDMA leads to redosing danger.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveFor PMMA (structurally related; PMA is a metabolite), lethal peripheral blood concentrations range from 0.6–3.1 mg/L and heart blood from 1.2–15.8 mg/L.[16]model confidence 75%
Abstract confirms peripheral lethal range 0.6–3.1 mg/L. Heart blood range (1.2–15.8 mg/L) is not mentioned in the abstract and cannot be verified; likely in the full paper's data tables.
Median fatal PMMA blood concentration 1.92 mg/L (lethal range 0.6-3.1 mg/L peripheral).
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveOnset of subjective effects is consistently described as 60–90 minutes to 2+ hours — markedly slower than MDMA (30–60 minutes)[9]model confidence 70%
Abstract confirms slower onset but provides no specific timing figures (60–90 min to 2+ hrs). Cannot verify the quantitative claim from the abstract alone.
Discusses slower onset leading to re-dosing danger.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA is a metabolite of PMMA via CYP2D6-mediated N-demethylation[21]model confidence 93%
Abstract confirms PMA as PMMA metabolite and CYP2D6 involvement in PMMA metabolism. N-demethylation is the only chemically possible pathway.
PMA is a minor metabolite of PMMA. CYP2D6 genetics significantly impacts PMMA metabolism.
checked by claude-sonnet-4-6 · Apr 25, 2026
clinical evidence7 claims5verified1partial1inconclusive
verifiedForensic case reports documenting fatal and near-fatal intoxications[15]model confidence 97%
Abstract describes a PMA overdose case and literature review — clearly a forensic/clinical case report documenting serious PMA intoxication.
PMA is a substituted synthetic amphetamine with high incidence of significant morbidity and mortality in overdose. Case of PMA overdose in South Australia.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedForensic case reports documenting fatal and near-fatal intoxications[18]model confidence 99%
Abstract describes three fatal PMA/PMMA cases in Denmark — directly a forensic case report documenting fatal intoxications.
Three fatal cases in Denmark 2000. Lethal blood concentrations of PMA/PMMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedForensic case reports documenting fatal and near-fatal intoxications[8]model confidence 99%
Abstract describes three fatal PMA cases with forensic analysis — directly supports the claim of forensic case reports on fatal intoxications.
Three fatal PMA cases with blood concentrations 10-27 mg/L. Cause of death: acute cardiorespiratory failure.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedIn vitro receptor and transporter studies[1]model confidence 97%
This paper is an in vitro study of MAO-A/B inhibition — directly an in vitro receptor/enzyme pharmacology study.
Ki = 0.22 μM for MAO-A (mouse brain).
checked by claude-sonnet-4-6 · Apr 25, 2026
partialIn vitro receptor and transporter studies[3]model confidence 80%
This paper uses in vivo chronoamperometry in anesthetized rats — it is an in vivo transporter dynamics study, not in vitro as the claim states. The transporter study classification is correct, but 'in vitro' is inaccurate for this citation.
Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake...revealed by chronoamperometry.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedIn vivo animal microdialysis and behavioral pharmacology[23]model confidence 99%
Paper directly uses in vivo microdialysis in rats to measure 5-HT release, exactly matching this evidence-type label.
PMA and MDMA both increase extracellular 5-HT (726% and 482% respectively in substantia nigra).
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveEpidemiological reviews of amphetamine-type stimulant mortality[33]model confidence 65%
Abstract not available. The scope description is consistent with the claim (UK ATS deaths 1997–2007) but cannot be verified without abstract text.
checked by claude-sonnet-4-6 · Apr 25, 2026
safety34 claims26verified2partial6inconclusive
partialFatal blood concentrations range from 0.57 mg/L (in polydrug cases) to 27 mg/L (extreme overdose)[8]model confidence 82%
This paper confirms the upper bound of 27 mg/L but reports concentrations of 10–27 mg/L — the lower bound of 0.57 mg/L is not from this source. The full range as stated requires other citations.
Three fatal PMA cases with blood concentrations 10-27 mg/L.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedRespiratory failure and arrest.[16]model confidence 99%
Abstract explicitly lists respiratory distress and cardiac arrest among fatal symptoms.
Fatal symptoms: respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveFatal blood concentrations range from 0.57 mg/L (in polydrug cases) to 27 mg/L (extreme overdose)[18]model confidence 65%
Abstract provides concentrations in mg/kg units (3.4 and 0.78 mg/kg), not mg/L as stated in the claim. Cannot directly verify the 0.57–27 mg/L range from this abstract.
Lethal blood concentrations of PMA/PMMA: 3.4/3.3 and 0.78/0.68 mg/kg.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedFatal blood concentrations range from 0.57 mg/L (in polydrug cases) to 27 mg/L (extreme overdose)[32]model confidence 97%
Abstract directly confirms PMA 0.57–0.59 mg/L in a fatal polydrug case, providing the lower bound of the claimed range.
PMA 0.57-0.59 mg/L in blood; ketamine and diazepam also detected.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedThe therapeutic index is described qualitatively as narrow, and PMA is consistently characterized as significantly more toxic than MDMA at equivalent doses.[3]model confidence 90%
Abstract states PMA's greater SERT inhibition may account for more severe adverse reactions, implicitly characterizing PMA as more toxic than MDMA.
PMA's greater SERT inhibition may account for more severe adverse reactions.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedThe therapeutic index is described qualitatively as narrow, and PMA is consistently characterized as significantly more toxic than MDMA at equivalent doses.[6]model confidence 93%
Abstract directly states PMA is associated with more severe hyperthermia than MDMA, cocaine, and methamphetamine, supporting greater toxicity at equivalent doses.
PMA associated with more severe hyperthermia than MDMA, cocaine, methamphetamine in humans.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveHyperthermia: The most common lethal mechanism. Core body temperatures exceeding 40–42°C have been documented. PMA-induced hyperthermia is more severe than that produced by MDMA, cocaine, or methamphetamine, driven by combined MAO-A inhibition, 5-HT release, and disruption of thermoregulatory behavior.[9]model confidence 70%
Abstract confirms hyperthermia in the case but does not provide temperature thresholds (40–42°C), describe it as the primary mechanism, or compare severity to MDMA/cocaine/meth. These details would require the full text.
16-year-old male found in coma with seizures, hyperthermia.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedHyperthermia: The most common lethal mechanism. Core body temperatures exceeding 40–42°C have been documented. PMA-induced hyperthermia is more severe than that produced by MDMA, cocaine, or methamphetamine, driven by combined MAO-A inhibition, 5-HT release, and disruption of thermoregulatory behavior.[6]model confidence 93%
Abstract directly supports the severity comparison (PMA worse than MDMA/cocaine/meth) and thermoregulatory disruption. The 40–42°C figure may be in the full text.
PMA associated with more severe hyperthermia than MDMA, cocaine, methamphetamine in humans. Thermoregulatory behavior disrupted by all four drugs.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedCardiovascular collapse: Acute cardiorespiratory failure is the most frequently cited cause of death in forensic studies.[8]model confidence 97%
Abstract directly cites acute cardiorespiratory failure as the cause of death in these fatal PMA cases.
Cause of death: acute cardiorespiratory failure.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveCardiovascular collapse: Acute cardiorespiratory failure is the most frequently cited cause of death in forensic studies.[15]model confidence 65%
Abstract documents PMA overdose with significant morbidity and mortality but does not specify 'acute cardiorespiratory failure' as the cause of death. This detail would be in the full case report.
PMA is a substituted synthetic amphetamine with high incidence of significant morbidity and mortality in overdose.
checked by claude-sonnet-4-6 · Apr 25, 2026
partialCardiovascular collapse: Acute cardiorespiratory failure is the most frequently cited cause of death in forensic studies.[18]model confidence 72%
Abstract cites 'multiple organ failure' as the cause of death in the Danish cases — overlapping with but distinct from 'acute cardiorespiratory failure.' The claim's specific mechanism isn't confirmed by this paper.
Multiple organ failure as cause of death.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedSeizures: Generalized convulsions are documented in multiple fatal and near-fatal cases.[9]model confidence 99%
Abstract directly documents seizures in this fatal PMA case.
16-year-old male found in coma with seizures, hyperthermia.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedSeizures: Generalized convulsions are documented in multiple fatal and near-fatal cases.[16]model confidence 99%
Abstract lists 'convulsions' as a fatal symptom in PMMA cases, directly supporting documentation of seizures.
Fatal symptoms: respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveMulti-organ failure: Including rhabdomyolysis, acute kidney failure, liver failure, and disseminated intravascular coagulation (DIC).[18]model confidence 70%
Abstract confirms 'multiple organ failure' as cause of death but does not specify the individual components (rhabdomyolysis, kidney failure, liver failure, DIC). These details would be in the full text.
Multiple organ failure as cause of death.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveMulti-organ failure: Including rhabdomyolysis, acute kidney failure, liver failure, and disseminated intravascular coagulation (DIC).[20]model confidence 70%
Abstract confirms 'multiorgan dysfunction' but does not enumerate the specific components (rhabdomyolysis, kidney/liver failure, DIC). Likely detailed in the full paper.
PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, then cardiovascular collapse.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedNicol et al. explicitly describe PMMA/PMA exposure as producing "multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse".[20]model confidence 99%
Abstract language is nearly verbatim: 'multiorgan dysfunction and serotonin syndrome, then cardiovascular collapse.'
PMMA exposure characterized by multiorgan dysfunction and serotonin syndrome, then cardiovascular collapse.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedHypoglycemia and hyperkalemia appear specific to PMA poisoning and may represent independent risk factors in fatal cases.[9]model confidence 97%
Abstract directly states hypoglycaemia and hyperkalaemia noted as possibly PMA-specific, directly matching the claim.
Hypoglycaemia and hyperkalaemia noted as possibly PMA-specific.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedAmphetamine-class intoxication carries a pooled rhabdomyolysis incidence of 30.5% (95% CI 22.6–38.5%) in a systematic review[34]model confidence 99%
Abstract exactly confirms: amphetamines 30.5% (95% CI 22.6–38.5%).
amphetamines (30.5%, 95% CI 22.6-38.5%)
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedCase reports and community sources describe dose-dependent anxiety and agitation at higher doses, with animal models confirming anxiogenic effects and unique immobility at higher doses[35]model confidence 97%
Abstract directly confirms dose-dependent anxiogenic effects at higher doses and unique immobility in an animal model.
higher doses showed anxiogenic effects similar to MDMA, plus immobility unique to PMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedGiven PMA's classification as a hallucinogen in some frameworks, such risks cannot be excluded but are uncharacterized.[5]model confidence 90%
Abstract confirms PMA's hallucinogen classification in the behavioral framework, which is the basis for the claim's reasoning.
PMA classified as hallucinogen (not entactogen or stimulant) by behavioral cluster analysis.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedCallaghan et al. demonstrated that repeated PMA administration (10–20 mg/kg for 4 days) produced significant reductions in cortical SERT binding (53% at 20 mg/kg) without reducing cortical 5-HT content[12]model confidence 99%
Abstract directly confirms 53% cortical SERT binding reduction without 5-HT content reduction under the stated regimen.
Repeated PMA (10-20 mg/kg for 4 days) reduced cortical SERT binding (53%) but unlike MDMA did not reduce cortical 5-HT content.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA does not maintain self-administration in rats and lacks amphetamine-like discriminative stimulus properties (only ~30% amphetamine-lever responding), indicating low reinforcing and dependence-forming potential compared to classical stimulants[7]model confidence 99%
Abstract exactly confirms both findings: no self-administration and only ~30% amphetamine-lever responding.
PMA does not maintain self-administration in rats (not reinforcing). PMA does not substitute for amphetamine in drug discrimination (only ~30%). Supports low addiction potential.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA failed to substitute for amphetamine in rhesus monkey discrimination paradigms.[36]model confidence 99%
Abstract directly confirms PMA produced little/no amphetamine-appropriate response in monkeys.
PMA produced little/no amphetamine-appropriate response in monkeys (up to 3-10 mg/kg).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA is itself a potent MAO-A inhibitor[1]model confidence 99%
Abstract directly and explicitly confirms PMA is a potent MAO-A inhibitor.
PMA is 20x more potent than (+)-amphetamine as MAO-A inhibitor.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedFreezer et al. demonstrated that moclobemide did not further increase PMA-induced 5-HT release at room temperature, because PMA already near-saturates MAO-A[2]model confidence 99%
Abstract exactly confirms moclobemide did not further increase PMA's 5-HT release, with the mechanism identified as MAO-A saturation.
Co-administration with moclobemide did not further increase PMA's 5-HT release but did for MDMA, suggesting PMA already saturates MAO-A.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedAt elevated ambient temperature (30°C), however, moclobemide combined with PMA produced 1450% peak striatal 5-HT increase and sustained hyperthermia.[28]model confidence 99%
Abstract directly confirms 1450% peak 5-HT increase at 30°C with moclobemide + PMA.
At elevated temperature (30°C), moclobemide + PMA produced 1450% peak 5-HT increase.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusiveTramadol, which inhibits 5-HT and NE reuptake and has weak MAO-inhibitory properties, combined with PMA would be expected to produce catastrophic serotonin syndrome based on convergent mechanistic pathways. MDMA combined with PMA is documented in multiple fatality reports: the slow onset of PMA and faster onset of MDMA means users may unknowingly combine both substances when re-dosing.[18]model confidence 65%
Abstract documents three fatal Danish cases with PMA/PMMA blood concentrations but does not mention MDMA+PMA combinations, re-dosing dynamics, or tramadol. The abstract cannot support or refute these specific claims.
Three fatal cases in Denmark 2000. Lethal blood concentrations of PMA/PMMA: 3.4/3.3 and 0.78/0.68 mg/kg.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedTramadol, which inhibits 5-HT and NE reuptake and has weak MAO-inhibitory properties, combined with PMA would be expected to produce catastrophic serotonin syndrome based on convergent mechanistic pathways. MDMA combined with PMA is documented in multiple fatality reports: the slow onset of PMA and faster onset of MDMA means users may unknowingly combine both substances when re-dosing.[37]model confidence 88%
Abstract documents a death from PMMA/PMA-containing ecstasy pills, directly supporting that MDMA (ecstasy) and PMA/PMMA combinations appear in fatality reports.
Death of 22-year-old after PMMA/PMA-containing ecstasy pills. Highlights that ecstasy pills may contain unexpected substances.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA is a weak Pgp inhibitor at concentrations far exceeding typical plasma levels — clinically unlikely to affect CNS penetration of co-administered drugs.[30]model confidence 99%
Abstract directly confirms weak Pgp inhibition at concentrations higher than in vivo levels, unlikely to affect brain access of co-administered drugs.
Weak Pgp inhibition at concentrations higher than in vivo levels; unlikely to significantly affect brain access of co-administered drugs.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedConcurrent MAO inhibitor therapy (including moclobemide, phenelzine, tranylcypromine, selegiline) is an absolute contraindication: the combination dramatically amplifies serotonin syndrome risk and can be lethal at any PMA dose.[2]model confidence 88%
Abstract demonstrates the mechanism by which MAO inhibitors interact with PMA (though in this case moclobemide did not further increase PMA's 5-HT at room temperature). Combined with elevated temperature data, this paper supports the mechanistic basis for MAOI contraindication.
PMA is MAO-A inhibitor. Co-administration with moclobemide did not further increase PMA's 5-HT release but did for MDMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedConcurrent MAO inhibitor therapy (including moclobemide, phenelzine, tranylcypromine, selegiline) is an absolute contraindication: the combination dramatically amplifies serotonin syndrome risk and can be lethal at any PMA dose.[28]model confidence 95%
Abstract directly demonstrates dramatic amplification: moclobemide + PMA at elevated temperature produced 1450% peak 5-HT, supporting the danger of MAOI + PMA combination.
At elevated temperature (30°C), moclobemide + PMA produced 1450% peak 5-HT increase.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedEpilepsy is contraindicated given documented seizures in PMA poisoning cases.[9]model confidence 99%
Abstract directly documents seizures in a fatal PMA poisoning case, supporting the epilepsy contraindication rationale.
16-year-old male found in coma with seizures, hyperthermia.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedEpilepsy is contraindicated given documented seizures in PMA poisoning cases.[16]model confidence 99%
Abstract lists convulsions as a documented fatal symptom, directly supporting the seizure contraindication.
Fatal symptoms: respiratory distress, hyperthermia, cardiac arrest, convulsions, multiorgan failure.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedHepatic and renal impairment are relative contraindications given multi-organ failure in severe toxicity cases and the likely role of hepatic CYP2D6 in PMA metabolism.[21]model confidence 90%
Abstract confirms CYP2D6 genetics significantly impacts PMMA metabolism (from which PMA is derived), supporting the hepatic CYP2D6 role in metabolism as a basis for the hepatic impairment contraindication.
CYP2D6 genetics significantly impacts PMMA metabolism.
checked by claude-sonnet-4-6 · Apr 25, 2026
comparative pharmacology9 claims8verified1inconclusive
verifiedWhen PMA is unknowingly ingested as MDMA, the delayed onset triggers re-dosing before first-dose effects manifest — a dynamic consistently identified as the primary driver of fatal overdoses.[8]model confidence 95%
Abstract directly links PMA's slower onset vs MDMA to re-dosing danger, supporting the claim that this dynamic drives fatal overdoses.
PMA more potent but slower onset than MDMA leads to redosing danger.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedRepeated PMA administration (10–20 mg/kg for 4 days) reduced cortical SERT binding by 53% without reducing cortical 5-HT content[12]model confidence 99%
Abstract exactly confirms the dose regimen, 53% SERT reduction, and no 5-HT content reduction.
Repeated PMA (10-20 mg/kg for 4 days) reduced cortical SERT binding (53%) but unlike MDMA did not reduce cortical 5-HT content.
checked by claude-sonnet-4-6 · Apr 25, 2026
inconclusivePMA onset is 60–120+ minutes[9]model confidence 70%
Abstract confirms slower onset than MDMA but provides no specific timing figure (60–120+ min). Cannot verify the quantitative claim from the abstract.
Discusses slower onset leading to re-dosing danger.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedMDMA produces greater absolute striatal 5-HT release (~590% vs. ~360% for PMA in rat microdialysis), but PMA achieves a higher net serotonergic burden through its concurrent MAO-A inhibition (Ki = 0.22 µM) — a mechanism absent from MDMA[2]model confidence 97%
Abstract confirms 360% vs 590% and that PMA is an MAO-A inhibitor. The mechanism of MAO-A being 'absent from MDMA' is supported by the finding that moclobemide further increased MDMA-induced 5-HT (implying MDMA does not saturate MAO-A).
PMA produced 360% increase in extracellular 5-HT (MDMA 590%). PMA is MAO-A inhibitor.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedMDMA produces greater absolute striatal 5-HT release (~590% vs. ~360% for PMA in rat microdialysis), but PMA achieves a higher net serotonergic burden through its concurrent MAO-A inhibition (Ki = 0.22 µM) — a mechanism absent from MDMA[1]model confidence 97%
This citation supports the MAO-A inhibition component of the claim: Ki = 0.22 µM confirmed exactly, and the >20-fold potency over amphetamine is confirmed.
PMA is 20x more potent than (+)-amphetamine as MAO-A inhibitor. Ki = 0.22 μM for MAO-A (mouse brain).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedThe MAO-A inhibitor clorgyline further potentiates MDMA (to 1033%) but not PMA, confirming PMA's endogenous MAO-A saturation.[23]model confidence 95%
Abstract confirms clorgyline potentiated MDMA but not PMA due to MAO-A saturation. The '1033%' figure is not in the abstract but the directional finding is clearly confirmed.
Adding clorgyline potentiated MDMA but not PMA (already saturating MAO-A).
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA produces more severe hyperthermia than MDMA, cocaine, or methamphetamine and disrupts thermoregulatory behavior[6]model confidence 99%
Abstract exactly confirms both elements: more severe hyperthermia than MDMA/cocaine/meth and thermoregulatory behavior disruption.
PMA associated with more severe hyperthermia than MDMA, cocaine, methamphetamine in humans. Thermoregulatory behavior disrupted by all four drugs.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedMDMA under comparable regimens reduces both SERT binding and 5-HT content, consistent with frank serotonergic axonal degeneration[12]model confidence 95%
Abstract states 'unlike MDMA did not reduce cortical 5-HT content,' implying MDMA does reduce both SERT binding and 5-HT content under comparable regimens, consistent with the claim.
Unlike MDMA did not reduce cortical 5-HT content. Different long-term neurotoxic profile from MDMA.
checked by claude-sonnet-4-6 · Apr 25, 2026
verifiedPMA does not maintain self-administration in rats and produces only ~30% amphetamine-lever responding in drug discrimination[7]model confidence 99%
Abstract exactly confirms both findings.
PMA does not maintain self-administration in rats (not reinforcing). PMA does not substitute for amphetamine in drug discrimination (only ~30%).
checked by claude-sonnet-4-6 · Apr 25, 2026
Coverage & Gaps
Research Trail
substance-article pipeline-v5 Apr 25, 2026
| Step | Source | Query | Results |
|---|---|---|---|
| 1database lookup | PubChem | para-methoxyamphetamine | 1 result, 1 selected |
selection rationaleselection rationaleOnly result; confirmed chemical identity | |||
| 2literature search | PubMed | PMA para-methoxyamphetamine pharmacology toxicity | 15 results, 15 selected |
selection rationaleselection rationaleAll selected as directly relevant to PMA pharmacology, toxicity, or case reports | |||
| 3literature search | PubMed | para-methoxyamphetamine deaths overdose case report | 6 results, 4 selected |
selection rationaleselection rationaleSelected case reports and forensic toxicology papers directly relevant to PMA death documentation | |||
| 4literature search | PubMed | PMA para-methoxyamphetamine MAO monoamine oxidase inhibition serotonin | 1 result, 1 selected |
selection rationaleselection rationaleDirectly relevant to PMA MAO-A inhibition mechanism | |||
| 5literature search | OpenAlex | para-methoxyamphetamine PMA pharmacology toxicology | 10 results, 3 selected |
selection rationaleselection rationaleSelected papers with direct PMA relevance; discarded wastewater analysis and general NPS reviews | |||
| 6literature search | PubMed | para-methoxyamphetamine serotonin releasing agent transporter inhibitor | 1 result, 1 selected |
selection rationaleselection rationaleKey mechanistic paper already found | |||
| 7clinical trial search | ClinicalTrials.gov | para-methoxyamphetamine PMA | 0 results |
selection rationaleselection rationaleNo trials - as expected for Schedule I drug not in clinical development | |||
| 8literature search | PubMed | p-methoxyamphetamine PMA monoamine oxidase A inhibitor Ki potency | 1 result, 1 selected |
selection rationaleselection rationalePrimary source for MAO-A Ki data | |||
| 9legal status search | WebSearch | PMA para-methoxyamphetamine DEA Schedule I legal status UK controlled drug | 10 results, 3 selected |
selection rationaleselection rationaleLegal status information for major jurisdictions | |||
| 10web search | WebSearch | PMA para-methoxyamphetamine DEA Schedule I scheduling history when first scheduled United States | 10 results, 2 selected |
| 11document retrieval | ADF Australia | — | 1 result, 4 selected |
| 12document retrieval | Release UK | — | 1 result, 2 selected |
| 13document retrieval | PubMed | Byard RW PMA paramethoxyamphetamine South Australia 1998 | 2 results, 2 selected |
| 14database lookup | PubMed | anise oil PMA precursor synthesis | 1 result, 1 selected |
| 15web search | WebSearch | PMA para-methoxyamphetamine UK deaths 2012 2013 | 10 results, 2 selected |
| 16web search | WebSearch | PMA first synthesis 1960s 1970s history discovery | 10 results, 2 selected |
| 17document retrieval | Erowid | — | 1 result, 4 selected |
| 18web search | WebSearch | PMA para-methoxyamphetamine EU Europe legal status Germany Netherlands | 10 results, 2 selected |
| 19literature search | PubMed | PMA drug discrimination stimulus properties hallucinogen | 3 results, 3 selected |
| 20literature search | PubMed | PMA moclobemide 5-HT temperature elevated ambient | 2 results, 1 selected |
| 21literature search | OpenAlex | PMA paramethoxyamphetamine serotonin syndrome death fatal overdose management | 8 results, 3 selected |
| 22cross reference | Multiple | PubChem SMILES verification and DOI verification | 3 results, 1 selected |
Research document (raw, unedited pipeline output)
# Research Output: PMA (para-Methoxyamphetamine) **PSX ID:** PSX-0302 **Research Date:** 2026-04-25 **Generation Provenance:** e0c836f5-f73e-49e3-a324-58a829ab2026 --- ## Chemical Identity PubChem lookup (CID 31721) confirmed the following chemical data, which was absent from the seed brief: - **IUPAC name:** 1-(4-methoxyphenyl)propan-2-amine - **Molecular formula:** C₁₀H₁₅NO - **Molecular weight:** 165.23 g/mol - **CAS number:** 64-13-1 - **PubChem CID:** 31721 - **InChIKey:** NEGYEDYHPHMHGK-UHFFFAOYSA-N - **SMILES:** CC(N)Cc1ccc(OC)cc1 (also written COC1=CC=C(CC(C)N)C=C1) **Note:** The seed brief contained no SMILES, formula, molecular weight, InChIKey, or PubChem CID. All have now been verified via PubChem [Ref 42 — database lookup]. **Stereochemistry:** PMA is chiral at the α-carbon. As a racemic mixture (±), street samples contain both the R and S enantiomers. No published human studies have investigated differential enantiomeric activity for PMA specifically, though this has been examined for related amphetamines in wastewater epidemiology [web-retrieved, not cited here]. The seed data does not specify stereochemistry; this remains an under-investigated area. **Physical appearance:** White or off-white crystalline powder, sometimes pressed into tablets that are sold as MDMA/ecstasy [Ref 31]. Common tablet branding encountered in case clusters includes "Red Mitsubishi" and tablets bearing a Rolex crown logo [Ref 32, web-retrieved]. Specific melting point data was not returned by PubChem and was not found in the reviewed literature; this is a gap. **Synthesis:** PMA can be synthesized via the Leuckart reaction starting from 4-methoxyphenylacetone (itself derived from anethole, a constituent of anise oil), producing PMA as a freebase or hydrochloride salt. Synthesis impurities include 4-methoxyphenol (specific to peracid oxidation route), and several methoxy-phenylpropyl ketimines (Waumans et al., 2003 [Ref 28]). The precursor anethole is cheap and largely unwatched by regulatory agencies compared to MDMA precursors, making clandestine synthesis accessible [Ref 28]. --- ## Pharmacology ### Mechanism of Action PMA is a trimodal monoaminergic agent that acts by three converging mechanisms, all elevating synaptic serotonin: **1. MAO-A Inhibition (primary distinguishing mechanism)** Green & El Hait (1980 [Ref 21]) characterized PMA as a potent, reversible, selective inhibitor of type-A monoamine oxidase (MAO-A) in mouse brain in vitro, with a **Ki = 0.22 µM** — over 20 times more potent than (+)-amphetamine as an inhibitor of 5-HT oxidation. Selectivity for MAO-A over MAO-B is pronounced: Ki for MAO-B is approximately 500 µM (benzylamine substrate, rat liver mitochondria). In vivo, PMA was 10 times more active than amphetamine at protecting mouse brain MAO from phenelzine inhibition [Ref 21]. This MAO-A inhibitory action prevents serotonin catabolism and is considered a critical contributor to PMA's enhanced serotonergic toxicity compared to MDMA. **2. Serotonin (5-HT) Releasing Agent / SERT Inhibitor** Freezer et al. (2005 [Ref 7]) demonstrated via rat microdialysis that PMA produces ~360% increase in extracellular striatal 5-HT (MDMA produced ~590% under the same conditions). Critically, PMA-evoked 5-HT release was partially blocked by a SERT inhibitor, indicating SERT-mediated release (efflux through the transporter), unlike MDMA which primarily releases dopamine in the striatum [Ref 8]. Callaghan et al. (2005 [Ref 8]) demonstrated using chronoamperometry in anesthetized rats that: - PMA causes less total neurotransmitter release than MDMA in striatum - PMA is a **more efficacious inhibitor of 5-HT clearance** than MDMA in the hippocampal CA3 region (which has only SERT, not DAT); the greater SERT inhibition in regions where only SERT clears 5-HT may account for PMA's more severe clinical toxicity Hewton et al. (2007 [Ref 12]) in rat substantia nigra microdialysis found PMA produced 726 ± 287% increase in extracellular 5-HT vs 482 ± 83% for MDMA. Critically, adding the MAO-A inhibitor clorgyline further potentiated MDMA (to 1033%) but NOT PMA, because PMA already near-saturates MAO-A at the doses tested — meaning PMA's own MAO-A inhibition is already operative [Ref 12]. **3. Dopamine (DA) and Norepinephrine (NE) Releasing Agent** Gołembiowska et al. (2016 [Ref 18]) using rat brain microdialysis showed PMA (5 and 10 mg/kg) enhanced DA and 5-HT release in striatum, nucleus accumbens, and frontal cortex. DA tissue content was increased in nucleus accumbens and frontal cortex by PMA. 5-HT tissue content was elevated in nucleus accumbens and frontal cortex. The authors note DA and NE release contributes to stimulant effects. No specific Ki/EC50 values at DAT or NET were identified in reviewed literature for PMA — FLAG for generation agent. Simmler et al. (2014 [Ref 24]) referenced PMA as releasing NE and 5-HT similarly to PMMA, 4-MTA, and MDMA in comparative in vitro transporter studies, but did not publish PMA-specific values in that paper. ### Classification Debate The pharmacological class of PMA is contested in the literature: - **Liechti (2015 [Ref 23])** classifies para-substituted amphetamines including PMA as **serotonergic entactogens** (serotonin-preferential releasing agents), similar to MDMA - **Hegadoren et al. (1995 [Ref 40])** classify PMA as a **hallucinogen** based on behavioral cluster analysis in rats — distinct from entactogens and stimulants - **Winter (1984 [Ref 36])** found PMA established clear discriminative stimulus control in rats independent of serotonergic mediation, but partial cross-generalization to LSD - The seed brief lists PMA's psychoactive class as both stimulant and entactogen; based on the literature, a third classification (hallucinogen) is supported by some animal data The DEA classifies PMA as a Schedule I **hallucinogen** [Ref 33]. ### Behavioral / Pharmacodynamic Profile **Rewarding effects:** Corrigall et al. (1992 [Ref 37]) found PMA does NOT maintain self-administration in rats and lacks amphetamine-like discriminative stimulus properties (only ~30% amphetamine-lever responding), suggesting lower reinforcing/addiction potential compared to classic amphetamines. Woolverton & English (1997 [Ref 38]) confirmed in rhesus monkeys that PMA failed to substitute for amphetamine in discrimination paradigms. Ponzoni et al. (2017 [Ref 39]) in zebrafish demonstrated PMA produces rewarding (CPP), prosocial, and anxiolytic effects, attributing these to 5-HT2A/C receptor activation and oxytocin/vasopressin (V1a) system engagement. **Aggression reduction:** Martín-López et al. (2018 [Ref 20]) showed PMA (2–12 mg/kg i.p.) reduced offensive behavior in male mice with a complex dose-dependent profile. Lower doses: increased social investigation; higher doses: anxiogenic effects similar to MDMA, plus unique immobility. **Thermoregulation:** Jaehne et al. (2007 [Ref 11]) showed PMA is associated with more severe hyperthermia than MDMA, cocaine, or methamphetamine, and disrupts thermoregulatory behavior in humans. This is the primary life-threatening mechanism. ### Pharmacokinetics **Published human pharmacokinetic studies for PMA are essentially absent from the reviewed literature** — this is a significant gap. The following is derived from case reports and animal studies: - **Route of administration:** Primarily oral; snorted or injected in some reports [Ref 31] - **Onset (oral):** Markedly slower than MDMA — clinical reports note onset of 60–90 minutes to 2+ hours, contributing to the characteristic re-dosing danger [Refs 4, 16, 32]. No formal Tmax data from controlled studies was found. - **Duration:** Estimated 6–8+ hours based on clinical presentations in case reports; formal duration data not found in controlled study - **Metabolism:** PMA is a minor metabolite of PMMA (N-demethylation) [Ref 19]. In the other direction, PMA's own metabolic pathway has not been formally characterized in humans. CYP2D6 is involved in PMMA metabolism (producing PMA), and by analogy CYP2D6 likely plays a role in PMA metabolism [Ref 19] - **Half-life:** No published human data found — FLAG - **Bioavailability:** No published human data found — FLAG **FLAG:** Absence of formal human pharmacokinetic studies is a major data gap for this substance. All dose/onset/duration data cited in any article draws from case reports or animal studies. ### Neurotoxicity Callaghan et al. (2006 [Ref 10]) found repeated PMA administration (10–20 mg/kg for 4 days) reduced cortical 5-HT transporter (SERT) binding by 53% at 10–20 mg/kg without reducing cortical 5-HT content (unlike MDMA which reduces both). PMA also reduced cortical 5-HIAA. This suggests a long-term alteration of 5-HT neurotransmission that differs mechanistically from MDMA's neurotoxicity — possibly a functional change rather than frank axonal degeneration. Straiko et al. (2007 [Ref 13]) found PMA (like MDMA) did not increase cleaved MAP-tau (a CNS toxicity marker) in rat striatum or hippocampus, unlike dopaminergic amphetamine/methamphetamine which did. C-tau increases were confined to astrocytes (reactive gliosis), and neither PMA nor the 5-HT selective neurotoxin 5,7-DHT triggered this, suggesting PMA's 5-HT effects are not neurotoxic via the DA-pathway mechanism. --- ## History **Early chemistry (1940s):** PMA was first described in the scientific literature circa 1946. Early pharmacological investigations emerged in the late 1960s studying substituted amphetamines [web-retrieved, unverified primary sources]. **1970s emergence as recreational drug:** PMA first appeared on illicit markets around 1970–1972, initially sold as a substitute for MDA and LSD rather than MDMA (which was not yet widely circulated). The first deaths attributable to PMA in the US were reported in 1972 [Ref 32]. In Ontario, Canada, between March and August 1973, nine fatalities among young users were directly attributed to PMA — one of the earliest documented recreational drug death clusters from this compound [Ref 32, web-retrieved]. These events prompted the DEA to schedule PMA as Schedule I (effective September 21, 1973, 38 FR 26447) [Ref 33]. **UK scheduling (1977):** The UK added PMA to Class A controlled substances via the Misuse of Drugs Act 1971 (Modification) Order 1977 (S.I. 1977/1243), effective September 20, 1977, under the generic phenethylamine structural clause [Ref 34]. **1980s quiescence:** PMA largely disappeared from illicit markets during the 1980s [Ref 32]. **1990s Australian resurgence:** PMA resurfaced in Australia in the early 1990s, marketed as MDMA/ecstasy. Byard et al. (1998 [Ref 27]) documented a series of amphetamine-derivative fatalities in South Australia, analyzing why deaths had increased markedly in that period. Caldicott et al. (2003 [Ref 2]) documented South Australian PMA overdose cases and provided management guidelines, noting PMA was known locally under the street name "death." **2000–2001 global cluster:** Approximately 20 deaths worldwide resulted from PMA sold as ecstasy [Ref 32]. Johansen et al. (2003 [Ref 3]) described three Danish fatal cases in 2000. Multiple case reports from this era documented deaths in Australia, Europe, and North America. **2010–2011 Norway epidemic:** July 2010–January 2011: 12 fatal PMMA intoxications and 22 non-fatal cases in Norway (population 4.8 million) over a 6-month period. This triggered broad media attention and an EMCDDA advisory [Vevelstad et al., 2012, Ref 14]. PMA was found as a metabolite in these cases at low concentrations (0.00–0.26 mg/L) [Ref 14]. **2012–2013 UK resurgence:** England and Wales recorded approximately 20 deaths in 2012, 29 in 2013 attributed to PMA/PMMA. In July 2013, seven deaths in Scotland were linked to tablets bearing a Rolex crown logo sold as ecstasy and containing PMA. Northern Ireland similarly saw deaths linked to "Green Rolex" pills [web-retrieved, Ref 32]. **Ireland:** Six deaths prompted an official public health warning (web-retrieved). **Canada:** Canada added PMA to Schedule I in 2012 [Ref 41]. Canadian deaths from PMMA/PMA were documented by Nicol et al. (2015 [Ref 29]) in Alberta and British Columbia. **Synthesis precursor context:** The Leuckart synthesis of PMA from anethole (anise oil) was documented by Waumans et al. (2003 [Ref 28]), highlighting that inexpensive, widely available precursors allow clandestine production, explaining PMA's continued use as a cheap adulterant in ecstasy tablets. --- ## Subjective Effects **No controlled human dosing studies were found in the reviewed literature.** The following is derived from clinical case descriptions, animal models, and community reports (primarily the ADF and Release resources): **Desired/sought effects (as reported by users and case descriptions):** - Moderate stimulation - Visual disturbances / heightened sensory perception - Sense of closeness and emotional warmth (entactogenic character) - Cognitive euphoria - Anxiolytic effects at lower doses [Ref 39, zebrafish model] - Prosocial effects [Ref 39] **Adverse acute effects (from case reports and ADF [Ref 31]):** - Hyperthermia (cardinal feature — more severe than MDMA [Ref 11]) - Tachycardia and elevated blood pressure (cardiac stimulation) - Dizziness, nausea, vomiting - Excessive sweating - Bruxism (teeth grinding) - Pupil dilation - Muscle spasms - Irregular eye movements - Decreased appetite - Anxiety and agitation (higher doses) - Immobility at high doses (animal model [Ref 20]) **Comedown effects:** - Anxiety, irritability, depression - Sleep disruption, exhaustion - Appetite loss - Concentration difficulties - Paranoia [Ref 31] **Critical behavioral note — slow onset and re-dosing danger:** PMA's oral onset is markedly slower than MDMA (estimated 60–120+ minutes vs. 30–60 min for MDMA). This is consistently identified as a primary driver of fatal overdoses: users who believe they have taken an ecstasy tablet containing MDMA, and feel no effects after 60–90 minutes, frequently take additional doses [Refs 4, 16, 31, 32]. The convergence of multiple doses then produces catastrophic serotonergic toxicity. This delayed onset/re-dosing dynamic is the most critical public health feature of PMA. **Duration:** Case report evidence suggests effects last 6–8+ hours. No formal duration data from controlled studies exists — FLAG. The seed brief contains no duration data, which is consistent with this absence in the literature. **Classification note:** Animal behavioral models classify PMA as a hallucinogen (not entactogen) with LSD-like serotonergic components [Refs 36, 40]. This may explain why some users describe visual effects alongside stimulation. --- ## Safety & Toxicity ### Lethal Blood Concentrations (from forensic case reports) | Source | PMA blood concentration | Outcome | |--------|------------------------|---------| | Johansen et al. 2003 [Ref 3] | 3.4 mg/kg and 0.78 mg/kg (with PMMA) | Fatal | | Becker et al. 2003 [Ref 6] | 0.61 mg/L (femoral blood; + PMMA 0.85 mg/L) | Fatal | | Jang et al. 2016 [Ref 17] | 0.57–0.59 mg/L (+ ketamine, diazepam) | Fatal | | Rojek et al. 2016 [Ref 16] | 10–27 mg/L | Fatal | **Note on the wide range:** The extraordinary range (0.57 to 27 mg/L) in fatal cases reflects polydrug toxicity at the low end (PMA alone insufficient) and extreme overdose at the high end. The narrow margin between intoxicating and lethal doses is a defining feature of PMA toxicity [Ref 16]. For PMMA (structurally related, PMA is a metabolite), lethal range: 0.6–3.1 mg/L in peripheral blood, 1.2–15.8 mg/L in heart blood [Ref 14]. **LD50 in animals:** No published LD50 data for PMA in humans was found. Animal LD50 data was not returned in the reviewed literature searches — FLAG. ### Mechanisms of Death Primary mechanisms from case reports and reviews: 1. **Hyperthermia:** The most common lethal mechanism. Body temperatures exceeding 40–42°C have been documented [Ref 4, Ref 31]. PMA's hyperthermia is more severe than MDMA's [Ref 11], driven by its combined MAO-A inhibition, 5-HT release, and disruption of thermoregulatory behavior 2. **Cardiovascular collapse:** Acute cardiorespiratory failure is the most frequently cited cause of death in forensic studies [Refs 16, 2, 3] 3. **Seizures:** Generalized convulsions documented in multiple fatal and near-fatal cases [Refs 4, 14] 4. **Multi-organ failure:** Including rhabdomyolysis, acute kidney failure, liver failure, DIC [Refs 3, 29, 31] 5. **Respiratory failure/arrest** [Ref 14] 6. **Electrolyte disturbances:** Hypoglycemia and hyperkalemia appear specific to PMA poisoning (as noted by Refstad 2003 [Ref 4]) and may be independent risk factors ### Serotonin Syndrome Features Clinical presentations are consistent with serotonin syndrome: hyperthermia, muscle rigidity/spasms, agitation, tachycardia, diaphoresis, clonus. Nicol et al. (2015 [Ref 29]) explicitly describe PMMA/PMA exposure as producing "multiorgan dysfunction and serotonin syndrome, followed by cardiovascular collapse." ### Rhabdomyolysis Amanollahi et al. (2023 [Ref 42]) found amphetamine class intoxication has a pooled rhabdomyolysis incidence of 30.5% (95% CI 22.6–38.5%) in a systematic review, with markedly elevated CPK and creatinine. PMA-specific rhabdomyolysis incidence not separately reported but would be expected within or above this range given the more severe serotonergic toxicity. ### Relative Toxicity Comparison PMA is consistently described as significantly more toxic than MDMA at equivalent doses: - Narrower therapeutic/toxic window - Slower onset increases accidental overdose risk - More potent MAO-A inhibition adds to serotonergic burden - More effective SERT inhibition in key brain regions [Ref 8] - More severe hyperthermia [Ref 11] Multiple sources characterize PMA as 5–10× more potent than MDMA in terms of toxic dose (web-retrieved; consistent with animal literature). The seed brief states PMA "can be considered extremely toxic when compared to other substances such as Methamphetamine or MDMA." This is confirmed by reviewed literature. --- ## Harm Reduction ### Primary Risk Factors 1. **Being sold as MDMA/ecstasy without disclosure** — the fundamental harm reduction problem. Drug checking (reagent testing or spectrometry) is the only reliable mitigation [Ref 25] 2. **Slow onset → re-dosing** — waiting 2+ hours before any additional dose if expected effects have not appeared [Ref 31] 3. **Dose sensitivity** — narrow therapeutic index means small absolute dose increases dramatically increase risk 4. **Hot/crowded environments** — elevated ambient temperature markedly potentiates PMA toxicity (Stanley et al., 2007 [Ref 35]: 5-HT outflow 4.7× higher at 30°C vs. 22°C with moclobemide combination) ### Drug Testing PMA is NOT reliably detected by standard immunoassay drug screens used in many emergency settings [Ref 6, noted that PMA/PMMA are absent from routine analytical procedures in many laboratories]. LC-MS/MS is required for reliable identification [Refs 15, 16]. Reagent testing (Marquis, Mecke) produces reactions different from MDMA but specific colorimetric results for PMA were not detailed in peer-reviewed sources found — FLAG. ### Emergency Response (from case report literature [Refs 2, 4, 31]) - Call emergency services immediately at onset of hyperthermia, seizures, loss of consciousness - Active cooling (ice packs, fans, cold IV fluids) is the priority intervention - Benzodiazepines for seizure control and agitation - Treat electrolyte abnormalities: hypoglycemia (glucose), hyperkalemia - Dantrolene has been discussed for severe hyperthermia (by analogy with malignant hyperthermia/NMS) but evidence base is weak - No specific antidote exists ### Contraindications (from literature) - **MAO inhibitors** (including moclobemide, phenelzine, tranylcypromine, selegiline): extremely dangerous; co-administration with any MAOI dramatically amplifies 5-HT surge [Refs 7, 12, 35] — **potentially lethal at any dose** - **Tramadol**: listed as lethal interaction in seed data; tramadol is a serotonin/norepinephrine reuptake inhibitor; combination with PMA (itself both a releasing agent and MAO-A inhibitor) would be expected to cause catastrophic serotonin syndrome. No specific published case studies of this combination were found, but the mechanistic rationale is extremely strong — FLAG for generation agent - **MDMA + PMA**: highly dangerous synergistic combination; multiple deaths involved both [Refs 3, 6]; the slow onset of PMA means users may add MDMA thinking the first pill has not worked - **Stimulants** (cocaine, methamphetamine): additive cardiovascular strain [Ref 31] - Cardiac conditions, hypertension, epilepsy, asthma [Ref 31] - Concomitant alcohol use amplifies negative effects [Ref 31] --- ## Tolerance & Dependence ### Tolerance Callaghan et al. (2006 [Ref 10]) showed repeated PMA administration (10–20 mg/kg for 4 days) produced significant reductions in cortical SERT binding (53% at 20 mg/kg), suggesting down-regulation of the serotonin transport system. This pattern resembles MDMA-induced tolerance mechanisms but differs in that PMA did not reduce cortical 5-HT content (unlike MDMA). This SERT down-regulation could underlie tachyphylaxis to PMA's serotonergic effects with repeated use, potentially driving dose escalation. No human studies on PMA tolerance development exist — FLAG. ### Dependence Corrigall et al. (1992 [Ref 37]) found PMA did NOT maintain self-administration in rats, suggesting low reinforcing/dependence-forming potential compared to classical stimulants. In drug discrimination, PMA did not substitute for amphetamine, further supporting a distinct abuse liability profile. ADF (2023 [Ref 31]) notes that while tolerance development is possible, physical withdrawal from PMA has not been documented. This is consistent with class-level evidence for serotonergic entactogens. **FLAG:** No published human data specifically addresses PMA dependence, withdrawal, or addiction. All dependence data is either structural class inference (from MDMA literature) or animal model extrapolation. --- ## Interactions ### Well-Documented Dangerous Interactions **MAO inhibitors (lethal risk):** PMA is itself a potent MAO-A inhibitor (Ki 0.22 µM [Ref 21]). Co-administration with any exogenous MAO inhibitor (reversible or irreversible, A-selective or non-selective) would compound MAO-A inhibition on top of PMA's serotonin-releasing activity, producing potentially lethal serotonin syndrome. Freezer et al. (2005 [Ref 7]) demonstrated that moclobemide did NOT further increase PMA-induced 5-HT release at room temperature (because PMA already near-saturates MAO-A). However, Stanley et al. (2007 [Ref 35]) showed that at **elevated ambient temperature** (30°C), moclobemide + PMA produced 1450% peak striatal 5-HT increase and sustained hyperthermia. The fatality of moclobemide + MDMA combinations (documented in humans) serves as a close analog for this risk. **Tramadol (listed as lethal in seed data):** Tramadol inhibits 5-HT and NE reuptake and also has weak MAO-inhibitory properties. Combined with PMA (which releases 5-HT and inhibits MAO-A), the resulting serotonin syndrome risk is extreme. This interaction is flagged as lethal in the Psychedex database. No published case series specifically documenting PMA + tramadol deaths was found in the reviewed literature. The mechanistic basis for the "lethal" classification is strong but the specific clinical evidence is not confirmable from this research alone — **FLAG for editorial review.** **MDMA (highly dangerous — documented in deaths):** Polydrug cases involving both PMA and MDMA are represented in multiple fatality case reports [Refs 3, 6]. The slow onset of PMA and faster onset of MDMA means users may unknowingly combine both substances. The combined serotonergic load is synergistic. **PCP (listed as dangerous in seed data):** PCP is an NMDA receptor antagonist/dissociative. Mechanism of interaction with PMA is not directly documented in reviewed literature — the combination would be expected to produce additive CNS effects (delirium, hyperthermia risk). No specific published case reports of this combination were found — FLAG. **Stimulants (cocaine, methamphetamine):** Additive cardiovascular effects (hypertension, tachycardia) and additive hyperthermia risk [Ref 31]. **Cannabis:** Seed data lists as "unknown." No published interaction data found. General serotonergic entactogen + cannabis combinations are not well-studied. ADF notes cannabis may increase anxiety and paranoia risk with PMA [Ref 31]. **Alcohol:** Seed data lists as "unknown." ADF notes alcohol amplifies negative effects [Ref 31]. No pharmacokinetic interaction data found. **P-glycoprotein:** Ketabi-Kiyanvash et al. (2003 [Ref 5]) found PMA is a weak Pgp inhibitor at concentrations much higher than typical plasma levels — unlikely to clinically affect CNS penetration of co-administered drugs. --- ## Legal Status | Jurisdiction | Status | Schedule/Class | Date | |-------------|--------|----------------|------| | **United States** | Schedule I Hallucinogen | DEA Schedule I | Effective September 21, 1973 (38 FR 26447, July 2, 1973) [Ref 33] | | **United Kingdom** | Class A, Schedule 1 | Misuse of Drugs Act 1971 | Effective September 20, 1977 (S.I. 1977/1243) [Ref 34] | | **Australia** | Schedule 9 Prohibited Substance | Poisons Standard | Current; South Australia involved in 1990s deaths [Ref 31] | | **Germany** | Highest control level | BtMG | Since September 1999 [Ref 41] | | **Netherlands** | Prohibited | — | Minister revoked legality June 13, 2012 (after five deaths) [web-retrieved] | | **Canada** | Schedule I | Controlled Drugs and Substances Act | 2012 [Ref 41] | | **New Zealand** | Class A | Misuse of Drugs Act | [Ref 41] | | **International** | Controlled | Convention on Psychotropic Substances, Schedule I | — | No analog act applicability issues were identified for the US, as PMA itself is directly scheduled. --- ## Clinical Trials **No clinical trials for PMA were found on ClinicalTrials.gov.** This is expected given its Schedule I status in most jurisdictions and its recognized toxicity profile. PMA has no current or historical medical use. --- ## Community Feedback Analysis No community feedback was submitted for PMA (Part A2 of the brief is empty). No feedback items to analyze. --- ## Gaps & Flags ### Safety-Critical Flags (require editorial attention before publication) 1. **⚠️ TRAMADOL INTERACTION listed as "lethal" in seed data** — Mechanistic basis is strong (serotonin syndrome via dual SERT inhibition + MAO-A inhibition), but no specific published case series documenting PMA + tramadol fatalities was identified. The classification is plausible but not confirmed from retrieved sources. Editorial review needed before publishing as confirmed. 2. **⚠️ PCP interaction listed as "dangerous" in seed data** — No published mechanistic or clinical data supporting specific PMA + PCP interaction was found. Could be class-level inference. FLAG for editorial review. 3. **⚠️ Dose data in seed brief (threshold 10mg, light 20-40mg, common 40-60mg oral)** — These values are not sourced in the seed data. No controlled human dosing studies were found in the reviewed literature. From case reports, fatal blood concentrations are highly variable (0.57–27 mg/L). The narrow therapeutic window means these dose tiers carry real lethality risk at the upper end. These dose ranges should be clearly marked as unconfirmed estimates (likely derived from user reports, not clinical studies). **⚠️ Safety-critical: any dose tier at the high end (≥40 mg) risks serious toxicity given the narrow therapeutic window.** ### Data Gaps 4. **Human pharmacokinetics absent:** No published human studies on PMA bioavailability, Tmax, half-life, or volume of distribution were found. All kinetic inferences are from case reports or structural analogy with MDMA. 5. **Duration data absent from literature:** No controlled studies provide duration data. The seed brief duration field is empty, consistent with this gap. 6. **LD50 data:** No published animal LD50 for PMA was retrieved. The therapeutic index is described qualitatively as "narrow" and PMA as "more toxic than MDMA" but quantitative LD50 was not found. 7. **Specific binding affinity values (Ki at DAT, NET, SERT):** Specific Ki/EC50 values for PMA at DAT and NET were not recovered from searched literature, though qualitative descriptions of DA/5-HT/NE releasing activity are well-supported. 8. **Melting point and detailed physical properties:** Not returned by PubChem, not found in literature searches. 9. **Stereochemistry:** No published data on differential pharmacological activity of R- vs S-PMA enantiomers was found. 10. **PMA physical appearance/tablet colors and logos** beyond those listed (Red Mitsubishi, Rolex crown): available only from community/web sources, not peer-reviewed. 11. **Contraindications (cardiovascular disease, epilepsy, asthma):** Listed in ADF resource but not sourced from published clinical studies; consistent with class-level amphetamine contraindications. 12. **Long-term neurotoxicity in humans:** Only animal data (SERT binding reduction) exists; human long-term consequences after PMA use are not described in published studies. ### Contradictions with Seed Data 13. **Psychoactive class:** Seed data lists "Stimulant, Entactogen" — literature also supports "Hallucinogen" classification (Winter 1984, Hegadoren 1995, DEA classification). Generation agent should include the disputed classification with sourcing. 14. **No SMILES/formula in seed data:** All chemical identity data was absent from the brief. Now confirmed via PubChem. 15. **Interactions list "Cannabis: unknown," "Alcohol: unknown":** Both remain unresolved in published literature. The ADF resource mentions these risks informally but no peer-reviewed data quantifies them.